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2  Summary 
Autoimmune hepatitis (AIH) is a chronic liver disease of unknown etiology, 
characterized  by  a  loss  of  tolerance  against  hepatocytes  leading  to  the 
progressive destruction of hepatic parenchyma and cirrhosis. Clinical signs 
for  AIH  are  interface  hepatitis  and  portal  plasma  cell  infiltration, 
hypergammaglobulinemia, and autoantibodies. Based on serological markers 
AIH is defined in subtypes. The hallmark of AIH type 2 are type 1 liver/kidney 
microsomal autoantibodies (LKM-1), whereas AIH type 1 is characterized by 
the  presence  of  anti-nuclear  (ANA)  and/or  anti-smooth  muscular  (SMA) 
autoantibodies.  The  major  autoantigen  recognized  specifically  by  LKM-1 
autoantibodies was identified as the 2D6 isoform of the cytochrome P450 
enzyme  family  (CYP2D6).  Not  much  is  known  about  the  etiology  and 
pathogenic  mechanisms  of  AIH  so  far  and  most  animal  models  available 
result in only transient hepatic liver damage after a rather complex initiation 
method. It was the aim of my project to generate a novel animal model for 
AIH  that  reflects  the  chronic  and  progressive  destruction  of  the  liver 
characteristic  for  the  human  disease  while  using  a  defined  and  feasible 
initiating event to further analyze the pathogenic mechanisms leading to the 
autoimmune-mediated destruction of the liver. Therefore, mice transgenically 
expressing the human CYP2D6 in the liver and wild-type mice were infected 
with a liver-tropic adenovirus expressing the human CYP2D6 (Ad-2D6). Self-
tolerance  to  CYP2D6  was  broken  in  Ad-2D6-infected  mice,  resulting  in 
persistent autoimmune liver damage, apparent by cellular infiltration, hepatic 
fibrosis and necrosis. Similar to type 2 AIH patients, Ad-2D6-infected mice 
generated  LKM-1-like  antibodies  recognizing  the  same  immunodominant 
epitope of CYP2D6. Taken together, we could introduce a new animal model 
that reflects the persistent autoimmune-mediated liver damage as well as the 
serological marker characteristic for AIH type 2 and we could demonstrate 
that  chronic  autoimmune  diseases  targeting  the  liver  can  be  triggered  by 
molecular mimicry occurring in the context of a hepatotropic viral infection.   6
3  Zusammenfassung 
Jeder  Organismus  wird  täglich  mit  vielen  verschiedenen  Antigenen  und 
Pathogenen konfrontiert. Um den Organismus gegen diese Fremdkörper zu 
schützen hat das Immunsystem verschiedene Schutzfunktionen entwickelt. 
Eine  der  wichtigsten  Voraussetzungen  des  Immunsystems  ist  es 
körpereigene  und  körperfremde  Antigene  unterscheiden  zu  können,  da  es 
sonst  zu  folgeschweren  Komplikationen  wie  Autoimmunerkrankungen 
kommen kann. Komplexe Selektionsmechanismen während der Reifung von 
Immunzellen als auch während dem Zusammentreffen von Immunzellen und 
Antigenen  führen  dazu,  dass  körpereigene  Antigene  toleriert  und 
körperfremde Antigene eliminiert werden. Diese Selektionsmechanismen sind 
jedoch nicht immer komplett gewährleistet oder können beeinflusst werden, 
so dass es unter gewissen Umständen zu Autoimmunerkrankungen kommen 
kann.  Zum  Beispiel  kann  ein  Pathogen,  das  sehr  ähnliche  molekulare 
Strukturen wie körpereigene Antigene aufweist, eine Immunantwort auslösen, 
welche  nicht  zwischen  körpereigen  und  körperfremd  unterscheiden  kann. 
Dieser  Vorgang  wird  auch  als molekulare Mimikry bezeichnet und  es  wird 
vermutet  dass  dies  eine  Ursache  für  Autoimmunerkrankungen,  wie  zum 
Beispiel rheumatisches Fieber und das Guillain-Barré-Syndrom, sein kann. 
Die  Leber  ist  das  grösste  innere  Organ  des  Menschen  und  dient  neben 
lebenswichtigen  Funktionen  wie  Entgiftung  und  Stoffwechsel  auch  als 
Speicher-  und  Ausscheidungsorgan  und  produziert  Gallensaft  zur 
Unterstützung  der  Fettverdauung.  Wegen  der  einzigartigen  Funktion  der 
Leber,  lebensnotwendige  nicht-körpereigene  Substanzen  wie  Nahrung  als 
auch  gefährliche  giftige  Stoffe  aus  der  Verdauung  abzubauen,  ist  es 
besonders  wichtig,  dass  Immunreaktionen  in  der  Leber  sorgfältig  reguliert 
werden.  Generell  tendieren  in  der  Leber  aktivierte  Immunzellen  eher  dazu 
Antigene  zu  tolerieren,  auch  wenn  dies  nicht  immer  der  Fall  ist,  wie  zum 
Beispiel bei der potenten Immunreaktion gegen den Hepatitis B Virus. 
Die Autoimmune Hepatitis (AIH) ist eine seltene chronische Lebererkrankung, 
bei der als Folge des Toleranzverlustes gegen hepatozelluläre Proteine eine   7
durch  das  körpereigene  Immunsystem  ausgelöste  Zerstörung  der 
Hepatozyten mit Übergang in eine Zirrhose zugrunde liegt. Klinisch ist die 
AIH  charakterisiert  durch  lymphozytäre  und  plasmazelluläre  Infiltrate  im 
Periportalfeld,  Hypergammaglobulinämie  und  Autoantikörper.  Serologisch 
lässt sich die AIH in Subtypen klassifizieren. Typisch für AIH vom Typ 1 sind 
Antikörper  gegen  Zellkerne  (ANA)  und  Antikörper  gegen  glatte  Muskulatur 
(SMA). LKM-1 Autoantikörper sind die serologischen Marker für AIH vom Typ 
2  und  reagieren  mit  immundominanten  Regionen  des  Isomers  2D6  der 
Enzymfamilie Zytochrom P450 (CYP2D6). Bis jetzt ist sehr wenig über die 
Krankheitsursachen  und  die,  der  Krankheit  zugrunde  liegenden 
Mechanismen  bekannt.  Zudem  fehlen  repräsentative  Tiermodelle.  Die 
meisten  Tiermodelle  für  AIH  konnten  nur  eine  vorübergehende  Hepatitis 
auslösen  und  benötigten  dazu  meistens  komplexe  krankheitsauslösende 
Mechanismen. 
Es war das Ziel meines Projekts ein neues Maus-Model für AIH zu entwickeln 
welches  die  chronische  Zerstörung  der  Leber  bei  menschlicher  AIH 
möglichst genau reflektiert. Zusätzlich sollte ein klar definierter und möglichst 
plausibler Auslöser für die Krankheit gewählt werden, um die Mechanismen, 
die zur autoimmunen Zerstörung der Leber führen, genauer untersuchen zu 
können. Dafür wurden wild-typ Mäuse (FVB/N Mäuse) und Mäuse, die das 
menschliche  CYP2D6  als  Transgen  in  der  Leber  exprimieren  (CYP2D6 
Mäuse)  mit  einem  lebertropen  Adenovirus,  der  das  menschliche  CYP2D6 
exprimiert  (Ad-2D6),  infiziert.  Als  Kontrollvirus,  der  keine 
Autoimmunerkrankung zur Folge haben sollte, wurde ein Adenovirus, der das 
grün  fluoreszierende  Protein  (Ad-GFP)  exprimiert,  gewählt.  Der  Gebrauch 
eines  Adenoviralen  Vektors  gewährleistet  sowohl  eine  hohe  als  auch 
spezifische  Expression  des  Transgenen  CYP2D6  in  der  Leber  der  Mäuse. 
Das  humane  CYP2D6  wurde  gewählt  da  Autoantikörper  spezifisch  für 
CYP2D6 das Hauptmerkmal zur Diagnose von AIH vom Typ 2 im Patienten 
sind  und  wild-typ  Mäuse  Zytochrom  P450  mit  hoher  Homologie  zum 
humanen CYP2D6 besitzen.   8
Durch  Infektion  von  wild-typ  FVB/N  und  CYP2D6  Mäusen  mit  dem 
Kontrollvirus  Ad-GFP  konnte  gezeigt  werden,  dass  die  virale 
Proteinexpression in der Leber nur vorübergehend war und dass schon nach 
zwei Wochen fast kein GFP mehr in der Leber exprimiert wurde. 
Infektion von wild-typ FVB/N sowie CYP2D6 Mäusen mit Adenovirus führte 
zu einer akuten virus-vermittelten Hepatitis mit vorübergehender Erhöhung 
der Leberwerte. Die Selbsttoleranz gegenüber CYP2D6 konnte jedoch nur in 
Ad-2D6-infizierten  Mäusen  durchbrochen  werden  und  nicht  in  Ad-GFP-
infizierten Mäusen. Das Durchbrechen der Toleranz führte zu lymphozytären 
und  plasmazellulären  Infiltraten,  Leberfibrose  und  Nekrose.  Dies  konnte 
durch  histologische  Analysen  gezeigt  werden.  Die  Mehrzahl  der 
infiltrierenden Zellen waren B-Zellen, CD4
+ T-Zellen und Makrophagen, wobei 
weniger CD8
+ T-Zellen gefunden wurden. 
Die  B-Zell  Toleranz  wurde  nur  nach  Ad-2D6  Infektion  durchbrochen  und 
führte zur Aktivierung von CYP2D6-spezifischen B-Zellen und zur Produktion 
und  Sekretion  von  CYP2D6-spezifischen  Antikörpern.  Diese  CYP2D6-
spezifischen Antikörper erkannten die gleiche immundominante Region des 
menschlichen CYP2D6 wie LKM-1 Antikörper von Patienten mit AIH vom Typ 
2. 
Interessanterweise zeigten die transgenen CYP2D6 Mäuse im Vergleich zu 
den  wild-typ  FVB/N  Mäusen  einen  abgeschwächten  autoimmunen 
Leberschaden, verspätete Immunzellinfiltrationen, weniger Leberfibrose und 
einen tieferen anti-CYP2D6 Antikörpertiter. Dies lässt die Vermutung zu, dass 
molekulare Ähnlichkeit (Maus Zytochrom P450 gegenüber humanen CYP2D6 
vom Ad-2D6), eine stärkere Autoimmunantwort auslösen kann als molekulare 
Gleichheit (CYP2D6 Mäusen gegenüber Ad-2D6). 
Injektion des humanen CYP2D6 Proteins in Kombination mit verschiedenen 
Adjuvantien  führte  zur  Produktion  von  CYP2D6-spezifischen  Antikörpern, 
aber nicht zu autoimmuner Hepatitis. Dadurch konnte gezeigt werden, dass 
in unserem System die virus-vermittelte Expression von CYP2D6 nötig war 
um autoimmunen Leberschaden auszulösen.   9
Die T-Zell Toleranz wurde ebenfalls nur nach Ad-2D6 Infektion durchbrochen. 
Dies  konnte durch ex-vivo  Stimulation  von T-Zellen  mit  CYP2D6  Peptiden 
und  der  darauf  folgenden  Produktion  von  Zytokinen  gezeigt  werden. 
Interessanterweise  konnte  eine  viel  höhere  Frequenz  an  Zytokin-
produzierenden  und  daher  CYP2D6  spezifischen  T  Zellen  aus  der  Leber 
isoliert werden als aus der Milz. Wie schon bei der Durchbrechung der B Zell 
Toleranz  konnte  in  wild-typ  FVB/N  verglichen  mit  transgenen  CYP2D6 
Mäusen eine stärkere Autoimmunantwort nachgewiesen werden. 
Zusammengefasst ist es uns gelungen ein neues Maus-Model zu etablieren, 
welches den chronischen autoimmunen Leberschaden und die serologischen 
Marker von AIH vom Typ 2 widerspiegelt. Zum ersten Mal konnte in einem 
Maus-Model die Produktion von Autoantikörpern mit derselben Spezifität wie 
menschliche LKM-1 Antikörper in AIH vom Typ 2 in Kombination mit einem 
chronischen  autoimmunen  Leberschaden  gezeigt  werden.  Zusätzlich 
konnten  wir  zeigen,  dass  eine  lebertrope  Virusinfektion  via  molekulare 
Mimikry eine chronische autoimmune Lebererkrankung auslösen kann. 
Dieses  Maus-Model  sollte  durch  die  Ähnlichkeit  zum  menschlichen 
Krankheitsbild der AIH vom Typ 2 und dem klar definierten und plausiblen 
Auslöser der Krankheit noch viel zu dem Verständnis der Mechanismen die 
zu AIH führen, beitragen können.   10
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7  Introduction 
7.1 Overview of the Immune system 
To protect an organism from infectious agents and the damage they cause a 
variety of mechanisms have evolved which have led to the complex immune 
system  of  vertebrates.  In  order  to  be  effective,  the  immune  system  must 
protect the individual against disease while limiting the damage made to the 
individual itself. 
The immune system can functionally be divided into two distinct parts that 
act  in  a  cooperative  way.  The  initial  non-specific  defenses  mechanisms 
against infections that are called the innate immune system and the adaptive 
immune system that displays a high degree of antigen-specificity. 
7.1.1 Innate Immune system 
Innate immunity provides the first line of defense against a wide range of 
invading  pathogens.  It  includes  anatomic,  physiologic,  phagocytic  or 
endocytic  and  inflammatory  barriers. The  skin  and the  surface  of mucous 
membranes  act  as  anatomic  barriers  by  preventing  entry  of  most 
microorganisms  and  the  low  pH  inhibits  growth  of  most  bacteria.  Saliva, 
tears and mucous secretion act to wash away potential invaders and contain 
antibacterial  or  antiviral  substances.  Physiological  barriers  include  body 
temperature and fever responses, which inhibit growth of some pathogens, 
gastric  acidity  that  kills  most  ingested  microorganisms  and  a  variety  of 
soluble  factors  like  lysozymes  that  cleave  bacterial  cell  walls,  interferons, 
which induce an antiviral state in uninfected cells and the complement that 
lyses  microorganisms.  The phagocytic  or  endocytic barrier  is  provided by 
white blood cells, such as blood monocytes, neutrophils, natural killer cells 
and tissue macrophages which are able to ingest and kill microorganisms by 
producing  a  variety  of  toxic  chemicals  and  degradative  enzymes.  The 
inflammatory response is a complex sequence of events that is caused by 
tissue  damage  or  invading  pathogenic  microorganism  and  leads  to   14
vasodilatation,  increased  capillary  permeability  and  influx  of  phagocytic 
active cells from capillaries into the tissue. The innate immune system is also 
responsible for the initial release of cytokines and chemokines that activate 
the adaptive immune system (1, 2). 
7.1.2 Adaptive Immune system 
Adaptive,  or  specific,  immunity  is  capable  of  recognizing  and  selectively 
eliminating specific foreign microorganisms and molecules. The four major 
characteristics of adaptive immunity are the antigen-specificity which permits 
the  immune  system  to  distinguish  subtle  differences  among  antigens,  the 
enormous  diversity  of  recognition  molecules  that  can  be  generated,  the 
immunologic  memory  that  enables  the  immune  system  to  respond  to 
previously  encountered  antigens  with  a  higher  reactivity  and  the  self  and 
non-self  recognition  which  enables  the  immune  system  to  distinguish  self 
from non-self. The ability of the immune system to distinguish self from non-
self  and  respond  only  to  non-self  molecules  is  essential  since  an 
inappropriate response to self molecules leads to autoimmune diseases and 
can be fatal. Adaptive immune responses can be divided into humoral and 
cell-mediated  responses.  The  two  major  groups  of  cells  of  the  adaptive 
immune system are the lymphocytes and the antigen presenting cells (APC), 
whereas the lymphocytes can be divided into B lymphocytes (B cells) and T 
lymphocytes (T cells) (1, 2). 
7.1.2.1 Lymphocytes 
T  and  B  lymphocytes  confer  specific  immunity  and  possess  specific 
receptors, the T and B cell antigen receptors, which are responsible for the 
enormous diversity of T and B cells and are able to discriminate between self 
and non-self.  
T Lymphocytes 
T  lymphocytes  express  a  T  cell  antigen  receptor  (TCR)  that  recognizes 
processed antigen peptides bound to cell-membrane proteins called major   15
histocompatibility  complex  (MHC).  T  lymphocyte  progenitors  arise  from 
hematopoietic stem cells in the bone marrow and migrate to the thymus to 
mature.  During  maturation  TCR  with  too  low  or  too  high  affinity  for  MHC 
molecules are deleted in a two-step selection process in the thymus. Positive 
selection of T cells ensures that mature TCRs bind to self-MHC molecules 
which confers MHC restriction (3). T cells with high affinity TCR for self-MHC 
molecules or self-MHC plus self-antigen undergo negative selection which 
ensures  self-tolerance.  T  cells  that  fail  positive  selection  or  get  negative 
selected  during  maturation  die  by  apoptosis.  As  a  result  of  this  two-step 
selection  process  about  99%  of  T  cells  die  within  the  thymus  during  the 
maturation  and  only  T  cells  that  are  self-MHC  restricted  and  self-tolerant 
survive  thymic  selection.  After  maturation  T  cells  can  be  divided  into  two 
distinct populations depending on their functional phenotype and expression 
of the CD4 or CD8 co-receptor. 
CD4
+ T helper cells (TH cells) are specific for antigenic peptides presented by 
MHC class II molecules and upon activation, proliferate and secrete various 
cytokines which in turn activate B cells, T cells, macrophages and other cells 
involved in the immune response. TH cells can be classified into TH1 and TH2 
cells based on their cytokine profile. The TH1 subset supports inflammation 
by secreting interleukin-2 (IL-2), interferon   (IFN- ) and tumor necrosis factor 
ß (TNF-ß) and is responsible for classical cell-mediated functions involving 
CD8
+ T cells. The TH2 subset supports mostly humoral immune responses 
involving  B  cell  proliferation  and  differentiation  into  antibody-secreting 
plasma  cells  and  memory  cells.  Other  groups  of  TH  cells  include  the 
regulatory T  (Treg)  and  TH-17  cell  populations.  Reductions  in  Treg  cells  may 
contribute  to  autoimmunity,  chronic  viral  infection,  tumor  immunity  and 
allergy while the role of the pro-inflammatory interleukin 17 (IL-17) secreting 
subgroup pertains probably to host defense and autoimmunity (4, 5). 
Activated CD8
+ cytotoxic T lymphocytes (CTL) recognize and lyse specifically 
own  cells,  which  present  foreign  antigenic  peptides  on  MHC  class  I 
molecules.  CTL  are  able  to  produce  IFN- ,  which  inhibits  viral  replication,   16
increases  expression  of  MHC  molecules  and  enhances  the  activity  of 
macrophages (1, 2). 
B Lymphocytes 
B lymphocytes express a B cell antigen receptor (BCR) that recognizes the 
native form of an antigen. Once a B cell is activated it secretes the BCR in a 
soluble form, referred to as an antibody. The basic unit of an antibody, or 
immunoglobulin  (Ig)  molecule  is  composed  of  two  identical  light  and  two 
identical  heavy  chains  that  are  stabilized  by  non-covalent  forces  and 
covalent disulfide bonds. The N terminal domains of the heavy as well as the 
light chains of different antibodies are extremely diverse and are responsible 
for the antigen binding site that recognize one specific B cell epitope, that 
consists typically of up to 22 amino acids on the surface of a foreign protein. 
B lymphocyte progenitors arise from hematopoietic stem cells and mature to 
B lymphocytes in the bone marrow. During maturation B cells go through 
several stages which are characterized by changes in the rearrangement of 
immunoglobulin  heavy  and  light  chain  genes  and  intracellular  as  well  as 
surface marker expression. Mature B cells leave the bone marrow and traffic 
to the B cell zone in secondary lymphoid organs, such as the spleen and 
lymph nodes. When a naïve B cell gets activated by encountering antigen in 
the presence of cytokines secreted by TH cells, the B cell starts to proliferate 
and differentiate into effector B cells called plasma cells that secrete large 
amounts of antibodies and into memory cells. Differentiating B cells produce 
IgM isotype antibodies and can upon activation, depending on the cytokines 
present, switch to different antibody classes (IgG, IgA and IgE) with different 
effector functions without changing the antigen-specificity (1, 2). 
7.1.2.2 Antigen processing and presentation on MHC molecules 
Every  cell  is  capable  of  presenting endogenous  antigens  on  class  I  MHC 
complexes  whereas  only  APC  display  endogenous  as  well  as  exogenous 
antigens on class I and class II MHC molecules. The best studied APC are 
macrophages, dendritic cells (DC) and B cells but it could be shown that   17
other  cells  such  as  liver  sinusoidal  endothelial  cells  are  able  to  present 
exogenous antigens on class II MHC molecules as well (6). 
Complexes between antigenic peptides and MHC molecules are formed by 
degradation  of  a  protein  antigen  by  two  different  antigen-processing 
pathways.  MHC  class  I  presentation  is  associated  with  the  processing  of 
endogenous antigens and MHC class II presentation with that of exogenous 
antigens. 
Endogenous  proteins  derived  from  normal  cells,  tumors,  viruses  or 
intracellular  bacteria  are  degraded  by  the  proteasome  into  peptides  and 
transported  into  the  rough  endoplasmic  reticulum  where  they  are  loaded 
onto  MHC  class  I  molecules.  MHC  class  I  molecules  preferentially  bind 
peptides of 8 – 13 amino acids. The peptide-loaded MHC class I molecules 
are transported through the Golgi complex to the cell surface, where they 
present the endogenous peptide to CD8
+ cytotoxic T cells 
Exogenous  antigens  are  internalized  by  APC  by  receptor-mediated 
endocytosis  in  all  APC  and  by  phagocytosis  and  macropinocytosis  in 
dendritic cells and macrophages. The internalized antigens are degraded into 
peptides  of  13  –  18  residues  within  the  acidic  compartments  in  the 
cytoplasm.  Within  the  endocytic  compartments  the  degraded  endogenous 
peptides  associate  with  the  MHC  class  II  molecules  transported  from  the 
rough  endoplasmic  reticulum  and  the  MHC  class  II-peptide  complex  is 
transported to the cell surface membrane, where the exogenous peptide is 
presented to CD4
+ T cells (1, 2) 
7.2 Tolerance 
Upon encountering an antigen, the immune system can either develop an 
immune response or enter a state of unresponsiveness called tolerance. The 
development of immunity or tolerance needs to be carefully regulated since 
an inappropriate response can have life-threatening consequences caused 
by immunity against self-antigens (autoimmunity) or tolerance to a potential 
pathogen.   18
7.2.1 Generation of Tolerance 
The first regulatory mechanism of the immune system to distinguish between 
self  and  non-self  is  called  central  tolerance.  It  occurs  during  lymphocyte 
maturation in the thymus and bone marrow when newly formed lymphocytes 
are especially sensitive to inactivation by strong signals through their antigen 
receptors, whereas the same signals would activate a mature lymphocyte. 
Since  central  tolerance  requires  the  presence  of  self-antigens  during  the 
maturation process of lymphocytes in the thymus and bone marrow and not 
all  self-proteins  can  be  present  during  that  time,  another  regulatory 
mechanism becomes necessary that controls maturated lymphocytes. This 
mechanism is called peripheral tolerance. Peripheral tolerance ensures that 
mature lymphocytes can distinguish between self and non-self even if they 
haven’t seen the antigen during their maturation. Peripheral tolerance often 
depends  on  how  the  mature  lymphocytes  encounter  the  not  yet  seen 
antigen.  High  and  constant  antigen  concentrations  from  self-proteins  can 
provide strong signals that tolerize mature lymphocytes. On the other hand 
suddenly  introduced  and  rapidly  increasing  foreign  antigens  as  during the 
early stages of an infection activate mature lymphocytes. The innate immune 
system  contributes  to  peripheral  tolerance  by  providing  signals  such  as 
cytokines  and  upregulation  of  co-stimulatory  molecules  on  APC  that  are 
crucial  in  enabling  the  activation  of  an  adaptive  immune  response  to 
infections. In the absence of infection these signals are not generated and 
the encounter of a naïve lymphocyte with a self antigen tends to lead to a 
negative, inactivating signal that leads to anergic (functional unresponsive) 
lymphocytes rather than no signal at all (7). The route of how an antigen is 
introduced  to  the  immune  system  can  have  effects  on  the  lymphocytes 
specific  for  that  antigen  as  well.  It  is  known  for  example  that  orally 
administered antigens tend to lead to oral tolerance. Oral tolerance induction 
is believed to be achieved by the induction of antigen-specific Treg cells that 
emerge  after  activation  in  the  gut-associated  lymphatic  tissues  under 
physiological conditions in the absence of inflammation. It has been shown 
that  these  weakly  self-reactive  Treg  cells  can  be  immunosuppressive  and   19
dampen other classes of immune responses in their immediate vicinity by 
secreting  non-inflammatory  TH2  cytokines  such  as  interleukin  4  (IL-4), 
interleukin 10 (IL-10) and tumor growth factor ß (TGF-ß) (1, 2, 8). 
7.2.2 Breaking  of  tolerance  –  induction  of  autoimmune 
disease 
Despite all tolerance mechanism the discrimination between self and non-self 
by the immune system is imperfect and self-reactive lymphocytes exist in the 
natural  immune  repertoire  but  are  not  often  activated.  In  autoimmune 
disease, however, these cells become activated and lead to tissue damage. 
7.2.2.1 Autoimmune diseases 
For  a  disease  to  be  defined  as  autoimmune,  the  tissue  damage  must  be 
shown  to  be  caused  by  the  adaptive  immune  response  to  self-antigens. 
Autoimmune  diseases  are  generally  classified  into  organ-specific 
autoimmune diseases that affect a specific organ and systemic autoimmune 
diseases that affect tissues throughout the body. Organ-specific autoimmune 
diseases  such  as  type  1  diabetes  mellitus  (T1D),  multiple  sclerosis  (MS), 
Graves’ disease, autoimmune hepatitis (AIH) or primary biliary cirrhosis (PBC) 
have  in  common  that  the  effector  functions  target  autoantigens  that  are 
restricted to particular organs: insulin-producing ß cells of the pancreas in 
T1D, the myelin sheathing axons in the central nervous system in MS, the 
thyroid-stimulating  hormone  receptor  in  Graves’  disease,  the  cytochrome 
P450 2D6 in hepatocytes in type 2 AIH or the bile ducts in the liver in PBC. 
Systemic  autoimmune  diseases,  such  as  systemic  lupus  erythematosus 
(SLE) or rheumatoid arthritis, cause inflammation in multiple tissues because 
their autoantigens like chromatin in SLE are not restricted to a specific organ 
but  rather  can  be found  in every cell  of  the  body.  For  many  autoimmune 
diseases  it  is  still  unknown  what  part of  the  immunesystem  mediates  the 
disease and in most cases it is likely to be a combination of several factors 
such  as  autoreactive  lymphocytes  and/or  their  soluble  products,  pro-
inflammatory  cytokines  and  autoantibodies.  The  etiology  of  most   20
autoimmune diseases is still largely unknown. However, it could be shown 
that autoimmune diseases are the result of multiple factors, including genetic 
predisposition and environmental triggers (1, 2). 
Genetic predisposition 
First  evidence  that  there  are  genetically  predispositions  in  humans  for 
autoimmune diseases came from the fact that some autoimmune diseases 
like T1D run in families. Further evidence was given by certain inbred mouse 
strains that are prone to various types of autoimmune disease like the non-
obese diabetic mouse line (NOD) for T1D (9). During the last decade new 
methodologies  were  able  to  link  genetic  factors  to  several  autoimmune 
disease. It could be shown that the MHC haplotype and polymorphisms in 
genes  involved  in  establishing  self-tolerance  and  immune  regulation  can 
influence the development of autoimmune diseases. The MHC haplotype for 
example can influence the susceptibility to a given autoimmune disease in 
two  ways.  It  can  either  ineffectively  present  self-antigens  in  the  thymus, 
which  leads  to  more  aggressive  T  cells  in  the  periphery  or  enhance  the 
presentation of peptide epitopes in the periphery which leads to increased T 
cell  activation.  Many  human  autoimmune  diseases  could  already  be 
associated with MHC haplotypes so for example T1D with HLA-DQ2/DQ8 
heterozygote (10), Graves’ disease with HLA-DRB3 (11) and AIH type 2 with 
HLA-DRB1 and HLA-DQB1 (12) to only name a few. Genetic polymorphism 
in genes like CTLA-4 or TIM proteins have been found that could be linked to 
autoimmune diseases in humans (Graves’ disease in case of CTLA-4) or in 
animal models (experimental allergic encephalomyelitis, an animal model for 
MS, in case of TIM proteins) further proving that genetic susceptibility factors 
can influence the development of autoimmune diseases (reviewed in (13)). 
Patients  with  a  defect  in  a  single  transcription  factor  called  autoimmune 
regulator (AIRE) that is responsible for turning on many peripheral genes in 
the thymus during central tolerance induction develop a rare inherited form of 
autoimmunity  called  autoimmune  polyendocrinopathy-candidiasis-  21
ectodermal  dystrophy  (APECED)  that  leads  to  the  destruction  of  multiple 
endocrine tissues (14). 
Environmental factors 
Genetic  variations  alone  are  not  always  sufficient  to  cause  autoimmune 
diseases, as it is the case for the very rare APECED disease. One prove that 
environmental factors must play a role in the etiology of autoimmune disease 
is  the  fact  that  there  is  a  considerable  discordance  in  the  incidence  of 
autoimmune diseases in human monozygotic twins as well as in genetically 
identical mice. There is also a decrease in incidence of autoimmunity from 
north to south in the northern hemisphere independent of ethnic background 
and a reduced incidence of autoimmunity in developing countries with poor 
sanitary  conditions  compared  with  industrial  countries  which  further 
substantiates the involvement of environmental factors in the manifestation 
of autoimmune diseases (15). 
However, how environmental factors influence the incidence of autoimmunity 
is still largely unknown. There are several theories how self-tolerance in an 
individual can be broken by environmental triggers leading to activation of 
auto-reactive lymphocytes and initiation of autoimmune disease. The most 
common theories that could be confirmed to induce autoimmune diseases in 
animal  models  are  bystander  activation,  molecular  mimicry  and  drug 
metabolism (see figure: Figure 1) (reviewed in (13)). It is likely however, that 
those theories alone can’t explain the induction of autoimmunity in humans 
by  itself.  It  has  become  clear  that  the  initiation  of  autoimmunity  is  a 
multifactorial  and  complex  process  that  requires  genetic  components  to 
synergize with environmental events (reviewed in (13)). Taken together, it is 
believed that microbial infection can induce a temporary immunological state 
that can, depending on other environmental and genetic factors yield in a 
pathological outcome of an infection leading to autoimmune diseases. This 
temporary immunological state is referred to as a ‘fertile field’ (16).   22
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Figure 1: Mechanism that can lead to broken self-tolerance 
(A) Infections lead to antigen-specific activation of the adaptive immune response. During 
that process however, there is always a proportion of non-specifically activated bystander-
lymphocytes at the site of infection. The sum of all non-specifically activated cells can cause 
damage to self-tissue. (B) An infection with a pathogen that resembles host molecules can 
lead to a pathogen-specific immune response that not only attacks the pathogen but also 
the self-tissue. (C) Drug metabolism can lead to the formation of protein adducts against 
which  the  immunesystem  could  not  induce  tolerance  against  leading  to  a  neo-antigen-
specific response against self-tissue (adapted from (13)). 
Bystander activation 
Despite all the tolerance mechanisms (see chapter: Generation of Tolerance) 
autoreactive B and T cells are present in all healthy subjects. However, these 
autoreactive  lymphocytes  alone  are  not  enough  to  initiate  autoimmune 
disease despite the presence of their autoantigen. Any infection leads to the 
release of pro-inflammatory cytokines that help the adaptive immune system 
to  accumulate  and  activate  pathogen-specific  lymphocytes  at  the  site  of   23
infection. However, since cytokines are soluble small proteins that can act in 
a  paracrine  as  well  as  endocrine  fashion  on  all  cells  that  express  the 
complementary  cytokine  receptors  there  will  always  be  some  antigen-
independent, non-specific lymphocyte attraction. In this context pathogen-
specific  lymphocyte  activation  can  lead  to  polyclonal  activation  of  non-
specific  as  well  as  pre-existing  autoreactive  lymphocytes.  This  antigen-
independent  lymphocyte  attraction  and  polyclonal  activation  of  potentially 
autoreactive lymphocytes is referred to as bystander activation (see Figure 1: 
(A)) (reviewed in (13)). As an example it has been shown that infection with 
Coxsackie virus during the pre-diabetic phase in NOD mice can accelerate 
T1D when their autoreactive T cells have reached a critical mass (17). 
Molecular mimicry 
Molecular mimicry has been defined as a structural similarity between host 
and pathogen (18, 19). An infection with a pathogen that confers molecular 
mimicry to host molecules can therefore lead to pathogen-specific antibodies 
that cross-react with ‘self’ or to the activation of autoreactive T cells (see 
Figure 1: (B)). One of the best studied animal model system for molecular 
mimicry  has  been  generated  using  transgenic  mice  that  express  the 
glycoprotein (GP) or nucleoprotein (NP) of lymphocytic choriomeningitis virus 
(LCMV)  under  the  control  of  the  rat  insulin  promoter  (RIP)  which  directs 
transcription  in  the  ß-cells  of  the  islets  of  Langerhans.  The  transgenically 
expressed  LCMV  proteins  in  these  mice  are  considered  self-proteins. 
However, upon infection of RIP-LCMV mice with LCMV these mice develop 
diabetes (20, 21). Several other animal models have been introduced that link 
infections with autoimmune diseases via molecular mimicry (22-24) making 
this  hypothesis  very  popular.  However,  so  far  there  is  very  little  direct 
evidence for the relevance of this theory for human autoimmune disease (19, 
25,  26).  Several  circumstances  make  it  difficult  to  identify  a  single 
microorganism as the cause of a human autoimmune disease. First, it is very 
likely that an acute infection that can induce autoreactive cells has already 
been cleared by the time these cells become auto-aggressive or at diagnosis   24
of  the  resulting  autoimmune disease, making  a causative  association  very 
hard to prove (also referred to as ‘Hit-and-run events’). Second, it is likely 
that in many cases a simple infection by one single infectious agent is not 
enough to initiate autoimmune diseases. It is possible that more then one 
subsequent  infection  is  needed  to  amplify  the  number  and/or  activation 
status of autoreactive cells and that the timing of those infections in relation 
to  each  other  plays  an  important  role,  which  in  retrospect  are  probably 
impossible  to  correlate  between  individuals  of  interest.  Third,  some  virus 
infections are extremely common and traces of these infections can be found 
in almost every individual and not only in those that develop autoimmune 
disease,  making  it  extremely  hard  to  associate  those  infections  with 
autoimmune  disease  (16).  The  two  best  documented  cases  for  molecular 
mimicry  in  human autoimmune  diseases  are  rheumatic  fever  and  Guillain-
Barré  syndrome.  In  rheumatic  fever  antibodies  that  appear  after 
Streptococcal pyogenes infections cross-react with heart autoantigens and it 
is postulated that this can lead to antibody-mediated and possibly T cell-
mediated anti-heart autoimmunity (27). In case of Guillain-Barré syndrome it 
could be shown that antibodies specific for Campylobacter jejuni appearing 
after  intestinal  infections  with  C.  jejuni  cross-react  with  peripheral  nerve 
gangliosides (28). 
Drug metabolism 
Another  evidence  of  external  causative  agents  in  human  autoimmunity 
comes from the effects of certain drugs, which elicit autoimmune reactions 
as side effects in a small proportion of patients. Those drugs are believed to 
initiate the autoimmune reaction by formation of neo-antigens to which no 
previous tolerance could have been established in the host (see Figure 1: 
(C)).  One  example  for  this  would  be  the  highly  reactive  intermediate 
trifluoroacetyl (TFA) that can covalently bind to self-proteins, resulting in the 
formation  of  protein  adducts.  TFA  is  generated  during  the  oxidative 
metabolism  of  2-bromo-2-chloro-1,1,1-trifluoroethane,  an  anesthetic  agent 
called halothane that is metabolized in the liver by cytochrome P450 2E1.   25
The formation of TFA protein adducts can in susceptible individuals lead to a 
specific immune response against these newly formed antigens and result in 
fulminant  autoimmune-mediated  hepatitis  with  a  frequently  fatal  outcome 
(29).  Interestingly,  although  the  formation  of  TFA  protein  adducts  can  be 
observed  in  all  individuals,  only  very  few  suffer  from  halothane  hepatitis 
suggesting  the  role  of  other  factors  in  disease  development.  Indeed,  the 
susceptibility  to  disease  is  suggested  to  be  linked  to  the  pyruvate 
dehydrogenase  complex  that  shares  a  structural  similarity  to  TFA  protein 
adducts and is aberrantly expressed in individuals with halothane hepatitis 
(29). Another well documented case is procainamide, a drug used to treat 
heart  arrhythmias,  and  its  metabolite  procainamide-hydroxylamine  that  is 
responsible for the induction of autoantibodies similar to those in SLE (13, 
30, 31). 
7.3 The liver 
7.3.1 Anatomy and function of the liver 
The liver is the largest internal organ in the human body and can be divided 
into four lobes based on surface features. The liver is essential for survival, 
plays  a  major  role  in  metabolism  and  detoxification  and  has  numerous 
functions  including  glycogen  storage,  decomposition  of  red  blood  cells, 
plasma protein and bile synthesis. The liver is the only organ receiving a dual 
blood supply, one from the hepatic arteries and the other from the portal 
veins draining the intestines, pancreas and spleen (see Figure 2: (A)). The 
liver tissue is organized around vascular bundles, which are known as portal 
tracts. From the portal tracts, blood flows through a sponge-like meshwork 
of sinusoids that exists between plates of hepatocytes allowing the liver to 
carry  out  its  physiologic  functions  of  digestion,  detoxification  and  plasma 
protein  synthesis  (see  Figure  2:  (B)).  The  sinusoids  are  lined  by  liver 
sinusoidal endothelial cells (LSEC) and contain liver resident macrophages, 
known as Kupffer cells, hepatic stellate cells, lymphocytes and immature DC. 
The unique blood circulation in the liver allows molecules absorbed by the   26
intestine to transit through the liver where they are metabolized or degraded 
if toxic. Because the liver is the major primary site of detoxification for the 
body  and  acts  as  a  first  line  of  defense  against  infectious,  toxic,  or 
carcinogenic agents arriving from the gut, the liver has evolved mechanisms 
that allow it to regenerate very quickly if injured (32, 33). 
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Figure 2: The liver and its microenvironment 
(A) The inputs and outputs of the liver showing the livers uniqueness by receiving blood from 
the hepatic arteries as well as from the portal veins draining the intestines, pancreas and 
spleen. (B) Diagram showing the structure of a liver lobule. The tissue is organized around 
portal tracts and the blood flows from them to the central veins, passing between plates of 
hepatocytes through spaces called sinusoids. This organization maximizes the exchange of 
molecules between the sinusoidal space and hepatocytes, allowing the liver to carry out its 
function (adapted from (33)). 
7.3.2 Liver immunology 
Already from the unique function of the liver to metabolize and detoxicate 
non-self molecules arriving from the intestine, a special role of the liver in 
controlling  these  mechanisms  locally  can  be  assumed.  Pathogenic 
microorganisms  must  be  efficiently  eliminated  while  the  large  number  of 
antigens  derived  from  harmless  food-derivates  must  be  tolerized  to  avoid 
damage  to  hepatocytes.  From  experimental  observations,  initially 
demonstrated by spontaneous acceptance of liver allografts in many species   27
(34) it is evident that the liver favors the induction of tolerance rather than the 
induction of immunity. Nevertheless, bacterial as well as viral infections occur 
within the liver and have to be cleared by the immunesystem. It could be 
shown  that  immunization  with  an  attenuated  sporozoite  can  protect  mice 
from experimental plasmodium infection and that this protection is mediated 
primarily by CD8
+ cytotoxic lymphocytes that persist in the liver for up to four 
months (35). It is also known that individuals are able to completely clear 
hepatitis viruses such as the hepatitis B virus (HBV), which is cleared in more 
then 95% of immunocompetent adults (36). On the other hand it could be 
shown in vitro that LSEC or Kupffer cells are able to endocytose, process 
and present antigen to T cells leading to local activation of T cells, however 
the most common outcome of T cell priming by LSEC is tolerance either by 
failure  of  CD8
+  T  cells  to  differentiate  into  cytotoxic  effector  cells  or  by 
induction  of  a  regulator  phenotype  in  CD4
+  T  cells  by  the  lack  of  co-
stimulatory signals of LSEC (37). It could also be shown that induction of 
peripheral tolerance to allograft antigens could be achieved by injection of 
donor-specific  leukocytes  prior  to  organ  transplantation  and  that  this 
tolerance depends on Kupffer cells, because it is impaired if the Kupffer cells 
are  depleted  (38,  39).  In  addition,  induction  of  T  cell  apoptosis  and 
accumulation  in  the  liver  occurring  as  a  function  of  insufficient  antigen 
presentation, defective T cell activation and deprivation of survival signals 
could be shown after T cell activation by hepatocytes suggesting a role for 
apoptosis in the immune regulation of the liver (40). In a recently published 
article it could be demonstrated that targeted expression of autoantigens in 
liver  cells  could  induce  autoantigen-specific  Treg  cells  that  were  able  to 
suppress  subsequent  induction  of  experimental  allergic  encephalomyelitis 
(EAE),  a  murine  autoimmune  disease  that  models  human  MS  (41).  Taken 
together  there  is  an  overall  bias  of  intrahepatic  T  cell  responses  towards 
tolerance. The underlying mechanisms that lead to reversal of this default 
state  of  tolerance  induction  in  the  liver  to  allow  priming  of  an  effector 
response are not completely understood yet. But the cytokine profile present 
during  antigen  presentation,  the  site  of  primary  activation  as  well  as  the   28
activation status of presenting APC are thought to play an important role (33, 
37). 
7.3.3 Liver diseases 
Liver disease is a broad term describing any number of diseases affecting 
the  liver.  Most  often  it  is  accompanied  by  hepatitis,  the  presence  of 
inflammatory cells in the liver. The condition can be self-limiting, healing on 
its own within a month, or progress to a more severe chronic form. Several 
viruses  such  as  Hepatitis  virus  A  through  E,  Herpes  simplex  virus, 
Cytomegalovirus,  Adenoviruses  and  Epstein-Barr  virus  can  cause  acute 
forms of hepatitis whereas only hepatitis B with or without hepatitis D and 
hepatitis  C  can  cause  chronic  hepatitis.  Several  toxins,  drugs  and  also 
alcohol  can  lead  to  acute  phase  hepatitis  and  in  some  cases  to  chronic 
forms. The breakdown of tolerance to self-antigens leads to autoimmunity 
(see chapter: Breaking of tolerance – induction of autoimmune disease) and 
can  result  in  chronic  inflammation  of the  liver  as  it  is  the  case  in  several 
autoimmune liver diseases described in the following chapter. Extensive and 
long-lasting liver damage can lead to development of fibrosis and cirrhosis, a 
consequence  of  chronic  liver  diseases  that  is  characterized  by  extensive 
deposition of extracellular matrix (ECM) proteins such as collagen types I, III, 
IV and V, laminin and elastin by hepatic stellate cells (HSC). While fibrosis, 
the  less  severe  form  of  cirrhosis  is  generally  still  reversible,  cirrhosis  is 
irreversible  and  in  advanced  stages  it  leads  to  a  complete  loss  of  liver 
functions (42). 
7.3.4 Autoimmune liver diseases 
Autoimmune  liver  diseases  (ALD)  include  a  spectrum  of  diseases  which 
comprises both cholestatic and hepatitic forms like primary biliary cirrhosis 
(PBC), primary sclerosing cholangitits (PSC), autoimmune hepatitis (AIH) and 
the  so  called  overlap  syndromes  where  hepatitic  and  cholestatic  damage 
coexists.  The  respective  syndromes  of  those  ALD  partially  overlap  and 
sometimes  a  definite  diagnosis  is  difficult,  because  clinical  signs  and   29
symptoms are often inconsistent and variable. However, all of those diseases 
can be severe, progressive and can lead to cirrhosis and death from end-
stage  liver  disease.  The  precise  etiology  as  well  as  the  exact  pathogenic 
mechanism  of  those  autoimmune  diseases  are  still  unknown  and  the 
diagnostic approach is mainly based on the detection and characterization of 
non  organ-specific  autoantibodies  and  the  responsiveness  to 
immunosuppressive therapy in case of AIH and to ursodeoxycholic acid in 
cholestatic conditions (43-45). 
7.3.4.1 Primary biliary cirrhosis 
PBC  is  a  chronic  cholestatic  liver  disease  characterized  by  the  slow 
progressive  destruction  of  intrahepatic  bile  duct  leading  to  fibrosis  and 
cirrhosis. It affects predominantly the female gender and is more common in 
first-degree  relatives  suggesting  a  genetic  predisposition  of  patients. 
However, no strict association with major histocompatibility complexe alleles 
could  be  found.  PBC  is  characterized  by  the  presence  of  detectable 
antimitochondrial  autoantibodies  (AMA)  in  approximately  90  –  95%  of 
affected individuals. The observation that patients lacking AMA have disease 
characteristics  and  progression  similar  to  those  of  AMA-positive  subjects 
appears  to  argue  against  a  pathogenic  role  for  these  autoantibodies.  The 
most  frequent  antigen  reactivity  of  AMA  is  against  the  subunit  E2  of  the 
pyruvate dehydrogenase complex (PDC-E2). The fact that this target antigen 
can be found on all cells of an organism but autoimmune attacks in PBC are 
organ-specific further suggests that AMA are not involved in the pathogenic 
mechanisms of PBC. About the etiology and pathogenesis of PBC is very 
little  known  so  far  but  the  main  proposed  hypothesis  includes  microbial-
mediated molecular mimicry as trigger in genetically susceptible individuals 
by Escherichia coli, Sphingomonas species or Helicobacter species (45-48). 
7.3.4.2 Primary sclerosing cholangitis 
PSC  is  a  progressive  cholestatic  liver  disease  characterized  by  the 
destruction of intra- and extra-hepatic bile ducts larger than those affected   30
by PBC also leading to fibrosis and cirrhosis. It occurs in children and young 
adults  and  is more  common  in men  than women.  The etiology  of  PSC  is 
unknown and despite the association with autoantibodies and inflammatory 
bowel disease its autoimmune origin is controversial. Diagnosis of PSC is 
most specifically achieved by the detection of structures of intra- or extra-
hepatic bile ducts via endoscopic retrograde cholangiopancreatography. The 
autoantibodies  found  in  about  90%  of  PSC  patients  are  anti-neutrophil 
cytoplasmic  antibodies  (ANCA).  However,  the  presence  of  these 
autoantibodies is not specific for PSC since they can be detected in other 
autoimmune  diseases  such  as  AIH  type  1  as  well.  Furthermore,  their 
presence does not appear to have a pathological role (43, 45, 49). 
7.3.4.3 Autoimmune hepatitis 
AIH  is  a  non-resolving  inflammation  of  the liver  of  unknown  cause  that  is 
characterized by the presence of interface hepatitis and portal plasma cell 
infiltration  on  histologic  examination,  hypergammaglobulinemia  and 
autoantibodies and leads to a loss of tolerance against hepatocytes and the 
destruction of hepatic parenchyma followed by cirrhosis and liver failure in 
almost all cases. There are no features that are absolutely diagnostic and the 
existence  of  the  condition  can  be  established  by  recognition  of  various 
compatible  features  and  the  exclusion  of  other  diseases.  Therefore  the 
international autoimmune hepatitis group standardized and published a list of 
criteria for the diagnosis of autoimmune hepatitis (50). Those criteria involve 
the gender, biochemical evaluations, various serum parameters, changes in 
the liver histology, genetic parameters, the exclusion of other liver diseases 
such  as  viral  markers  and  drug  or  alcohol  abuse/misuse  as  well  as  the 
outcome of immunosuppressive therapy. Liver biopsy examination as well as 
the presence of autoantibodies is essential to establish the diagnosis. Based 
on  the  autoantibodies  present  in  the  serum  of  patients  AIH  can  be 
subdivided into two major types, type 1 and type 2 AIH (51, 52). 
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Autoimmune hepatitis type 1 
The main serologic markers of type 1 AIH are antinuclear antibodies (ANA) 
and/or  smooth  muscle  antibodies  (SMA).  ANA  are  a  largely  non-specific 
marker of AIH and can also be found in other autoimmune liver disease, liver 
diseases in general and even in up to 15% of the general healthy population 
predominantly among older age groups. ANA have been found to be reactive 
with  centromers,  ribonucleoproteins,  cyclin  A,  histones  and  many  other 
antigens and so far no liver-specific or liver-disease-specific ANA has been 
discovered. SMA are directed against actin and non-actin components of the 
cytoskeleton  such  as  tubulin,  vimentin,  desmin  and  skeletin.  Actin-
associated SMA are found in a large majority of SMA-positive AIH patients 
but  are  rare  in  other  chronic  liver  diseases.  Positivity  for  actin-associated 
SMA  is  more frequently  seen  in patients  with  the  HLA  B8,  DR3  and  DR4 
haplotypes and is associated with early disease onset and worse prognosis. 
Autoantibodies against soluble liver antigen and liver-pancreas antigen (Anti-
SLA/LP) are the most specific autoantibody identified in type 1 AIH however, 
it is only found in 10 – 30% of cases (44, 51-54). 
Autoimmune hepatitis type 2 
Autoantibodies  to  liver-kidney  microsomal  type  1  antigens  (LKM-1)  have 
been  found  to  be  the  hallmark  of  AIH  type  2  and  the  target  antigen  was 
identified as the isoform 2D6 of the large cytochrome mono-oxygenase P450 
enzyme family (CYP2D6). LKM-1 antibodies in AIH type 2 recognize the linear 
CYP2D6254-271  sequence  as  immunodominant  but  not  exclusive  epitope  in 
almost all patients with AIH type 2 (55-58). However, LKM-1 antibodies also 
occur in up to 10% of sera from patients chronically infected by hepatitis C 
virus (56). Antibodies to liver-cytosol type 1 (LC1), another autoantibody that 
is  found  in  up  to  50%  of  patients  with  AIH  type  2,  recognize 
forminminotransferase  cyclodeaminase  (FTCD),  a  liver-specific  metabolic 
enzyme. Susceptibility factors for AIH type 2 are associated primarily with 
HLA-DRB1 and HLA-DQB1 (59).   32
The pathogenic mechanism underlying AIH type 2 are still unknown. It could 
be shown that CYP2D6, the target recognized by LKM-1 antibodies is not 
exposed  on  the  surface  of  hepatocytes  excluding  antibody-mediated  cell 
lysis  directed  against  membrane  CYP2D6  (58).  On  the  other  hand  more 
recent data could show that LKM-1 autoantibodies do recognize and bind to 
CYP2D6  exposed  on  the  plasma  membrane  of  hepatocytes  (60)  and  that 
anti-LC1  antibodies  seem  to  correlate  with  disease  activity  suggesting  a 
pathogenic role of autoreactive B cells in AIH type 2 (61). Very recently it 
could also be shown that MHC class I as well as class II restricted immune 
responses seem to influence autoimmunity in patients with AIH type 2 (59, 
62, 63). However, the exact mechanisms of the pathogenesis remain unclear. 
Another unsolved problem of AIH is its etiology. A common hypothesis to 
explain the etiology of autoimmune diseases is genetic predisposition of the 
host paired with environmental triggers (see chapter: Autoimmune diseases). 
As previously explained (see chapter: Environmental factors) infections are 
the prime candidates for initiating autoimmunity in predisposed individuals 
since they frequently induce strong inflammatory responses in various organs 
and  can  therefore  attract  a  multitude  of  potentially  autoaggressive 
lymphocytes to the site of infection (13). Although a direct link between AIH 
and viral or bacterial infections has not been proven to date, there are several 
experimental findings that add credence to a hypothesis of virally triggered 
AIH. First, it is known that a significant number of AIH type 2 patients carry 
antibodies  to  HCV  (64).  Second,  it  could  be  shown  that  sera  of  38%  of 
chronic  HCV-infected  patients  reacted  specifically  with  CYP2D6,  whereas 
none  of  the  sera  from  patients  with  chronic  hepatitis  B  showed  CYP2D6 
reactivity (65). In addition, it was found that HCV has the potential to induce 
autoreactive CD8
+ T cells, which cross-reactively recognize the cytochrome 
P450 isoforms 2A6 and 2A7 that contain sequence homology to HCV (66). 
Furthermore, it could be shown that antibodies against CYP2D6 in HCV and 
LKM-1  positive  patients  can  cross-react  with  the  HCV  proteins  NS3  and 
NS5a  (56)  and  that  CYP2D6-specific  antibodies  could  be  found  in  HCV-
infected patients (67). In addition, other sequence homologies like between   33
the immunodominant CYP2D6 epitope and a protein of herpes simplex virus 
1 (HSV-1) have been reported (57). Such a phenomenon of cross-reactivity 
on  the  level  of  T  cell  or  antibody  recognition  is  commonly  referred  to  as 
‘molecular  mimicry’  (see  chapter:  Environmental  factors)  and  remains  a 
favored  hypothesis  for  the  initiation  of  autoimmunity  in  general  or 
autoimmune liver diseases as PBC or AIH type 2 although the definite proof 
remains elusive. 
7.3.4.4 Overlap syndromes 
Overlap syndromes are diagnoses made by clinicians who felt that a single 
designation  is  inadequate  to  convey  the  mix  of  clinical,  laboratory  and 
histological  features  of  a  disease  process.  For  example,  the  classical 
description of AIH does not involve the presence of AMA, high serum levels 
of alkaline phosphatase or the histological features of destructive cholangitis. 
In addition, the classical diagnosis of PBC does not involve the presence of 
increased  serum  levels  of  aminotransferase  and  IgG  and  the  histological 
findings of moderate to severe interface hepatitis. However, those diagnoses 
exist and are commonly referred to as overlap syndromes or more precisely 
as hepatitic PBC or cholestatic AIH (68). 
7.3.4.5 Animal models for AIH 
Animal  disease  models  are  an  invaluable  resource  in  elucidating  the 
pathogenic mechanisms underlying complex conditions such as autoimmune 
diseases  and  are  widely  studied  by  immunologists  (see  chapter: 
Environmental factors). However, animal models for AIH have proven difficult 
to generate and none of them have covered all the attributes that are linked 
to  the  autoimmune  destruction  of  hepatocytes  occurring  in  human  AIH, 
perhaps at least in part because of the overall bias of intrahepatic immune 
responses towards tolerance (see chapter: Liver immunology). Breaches of 
tolerance leading to autoimmunity and hepatitis have been demonstrated but 
often depend on a rather complex disease induction protocol and hepatitis 
was in most cases only transient. In most animal models for AIH a transgenic   34
target  antigen  expressed  specifically  in  the  liver  is  used  to  target  the 
autoaggressive immune response to the liver (69, 70). 
In  the early  1990s  a  HBV  surface antigen  (HBsAg)  transgenic  mouse  was 
developed  that  expressed  the  HBsAg  under  the mouse albumin  promotor 
and therefore specifically in the liver. Upon adoptive transfer of activated T 
cells  from  HBsAg-primed  donor  mice  they  found  liver  infiltrating  HBsAg-
specific  CTL  targeting  HBsAg  expressing  hepatocytes.  However,  only  a 
transient form of hepatic injury could be observed (71). 
In  another  model,  the  MHC  class  I  molecule  H-2K
b  was  transgenically 
expressed in the liver of mice that were carrying in addition T cells with a 
transgenic TCR specific for H-2K
b. Those mice displayed peripheral tolerance 
to H-2K
b that could only be broken by transferring cells expressing the H-2K
b 
target  antigen  and  IL-2  or  by  infecting  the  mice  with  a  liver-specific 
pathogen,  indicating  that  bystander  activation  within  the  liver 
microenvironment  is  necessary  to  break tolerance and cause autoimmune 
tissue damage (72). 
Further, a model similar to the RIP-LCMV mouse model for type 1 diabetes 
(see chapter: Environmental factors) was described with the difference that 
the GP was expressed under the control of the albumin promotor exclusively 
in the liver. As in the RIP-LCMV model these mice did not show any signs of 
autoimmunity under normal conditions and similar to the H-2K
b transgenic 
mice, adoptive transfer of TCR transgenic T cells specific for the LCMV-GP 
expressed in the liver alone was not sufficient to induce disease. However, 
when these mice were infected with LCMV after adoptive transfer a transient 
form of hepatitis developed (73). 
In  another  study,  mice  expressing  the  LCMV-NP  under  the  control  of  the 
transtyretin promotor specifically in the liver were vaccinated with plasmids 
expressing the LCMV-NP. Liver injury characterized by cellular infiltration and 
elevated serum aminotransferase levels could only be detected after plasmid 
vaccination in combination with the TH1 stimulating cytokine interleukin-12 
(IL-12) (74).   35
A related approach was used in another study in which wild-type mice were 
xenoimmunized  with  a  plasmid  containing  the  human  antigenic  region  of 
CYP2D6  (the  target  of  LKM-1  antibodies)  and  FTCD  (the  target  of  LC1 
antibodies). However, minor elevations in serum aminotransferase levels, a 
transient generation of anti-CYP2D6 and anti-LC1 antibodies and significant 
inflammation  in  the  liver  could  only  be  found  after  co-expression  of  IL-12 
(75).   36
8  Aim of the study 
It  was  the  aim  of  my  project  to  generate  a  novel  animal  model  for 
autoimmune  hepatitis  that  reflects  the  chronic  inflammation  and  the 
progressive  destruction  of  the  liver  characteristic  for  the  human 
disease. In addition, we were interested in the mechanism underlying 
this  autoimmune  liver  damage  and  the  potential  contributions  of 
humoral and cellular immunity to hepatic autoimmunity. 
8.1 Strategy 
A  common  hypothesis  to  explain  the  etiology  of  autoimmune  diseases  is 
genetic  predisposition  of  the  host  paired  with  environmental  triggers, 
whereas infections remain the prime candidates for initiating autoimmunity 
since they frequently induce strong organ-specific inflammatory responses. 
In addition, it could be shown that viruses can induce, accelerate and even 
prevent  autoimmune  processes  in  animal mouse models most  likely  via  a 
process called molecular mimicry (see chapter: Environmental factors) (76). 
Nevertheless,  no  direct  link  between  autoimmune  hepatitis  and  viral 
infections could be found yet even though several studies implicate viruses in 
its initiation. In animal models for autoimmune liver diseases an often only 
transient form of autoimmune-mediated liver damage could only be achieved 
with rather complex ways of induction. Our strategy was therefore to build an 
animal model on the initial concept of molecular mimicry by virus infection 
and see if viral inflammation caused by liver-tropic adenovirus can facilitate 
the  breaking  of  tolerance  to  a  naturally  occurring  autoantigen  in  the  liver 
(CYP2D6) resulting in a chronic form of severe, autoimmune liver damage. 
8.1.1 The CYP2D6 humanized mice 
The  CYP2D6  humanized  mouse  line  was  generated  by  Frank  J.  Gonzalez 
(National Cancer Institute, U.S. National Institutes of Health, Bethesda, MD) 
to overcome the species differences between animal models and human in 
preclinical  studies  on  the  pharmacology,  toxicology,  and  physiology  of   37
CYP2D6-mediated  metabolism.  Therefore  the  complete  CYP2D6  gene 
(GenBank accession number M33388), including its promoter and regulatory 
elements, was microinjected into a fertilized FVB/N mouse egg to produce a 
transgenic mouse line. Successful incorporation of the CYP2D6 DNA within 
the mouse genome was determined by both PCR and southern blot analysis 
(see Figure: Figure 3 (A) and (B)). The transgene was present at 5 ± 1 copies 
per haploid genome. Expression of the transgenic protein was assessed by 
western blotting and CYP2D6 expression was found in liver, intestine and 
kidney microsomes only (see Figure: Figure 3 (C)). Debrisoquine hydroxylase 
activity was enhanced in CYP2D6 transgenic mice compared with wild-type 
mice, indicating that CYP2D6 in humanized mice is functional (77). 
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Figure 3: Generation and analysis of the CYP2D6 humanized mouse 
(A) Southern blot genotyping of wild-type FVB/N and CYP2D6 humanized mice. Tail DNA 
was digested and probed with CYP2D6 cDNA. (B) PCR genotyping of wild-type FVB/N and 
CYP2D6 humanized mice. Tail DNA was amplified with mouse epoxide hydrolase (mEH) and 
CYP2D6 gene-specific primers. (C) Western blot analysis of CYP2D6 protein expression in 
wild-type  FVB/N  and  CYP2D6  humanized  mice.  Liver  (L),  intestine  (I)  and  kidney  (K) 
microsomal  proteins  were  separated  and  stained  with  a  human  CYP2D6-specific 
monoclonal antibody. Human liver microsomes (HLM) were used as a control (adapted from 
(77)). 
The cell-specific expression of human CYP2D6 in liver, kidney and intestine 
in humanized mice was similar to that reported in humans. In addition, the 
orthologous  mouse  cytochrome  P450  isoenzymes  (CYP2Ds)  that  are 
expressed in wild-type FVB/N mice as well as in humanized CYP2D6 mice 
showed a similar expression pattern to those in humans in liver and kidney   38
(78).  There  are  at  least  nine  different  mouse  CYP2Ds  genes  and  one 
isoenzyme, CYP2D22, has been suggested to be the functional ortholog of 
CYP2D6 (79). Mouse CYP2Ds genes display high sequence homology of the 
human CYP2D6 and other human CYP isoenzymes and by screening of the 
National Center for Biotechnology Information databank we could show that 
the  mouse  CYP2Ds  isoenzymes  CYP2D9,  CYP2D11,  CYP2D22  and 
CYP2D26 display up to 75% aa sequence homology to human CYP2D6 (80). 
8.1.2 Adenoviruses 
Adenoviruses are medium-sized  (90 –  100 nm),  nonenveloped  icosahedral 
viruses  composed  of  a  nucleocapsid  and  a  double-stranded  linear  DNA 
genome  that  are generally  associated with benign  pathologies  in humans. 
Since  adenoviruses  deliver  their  genome  to  the  nucleus  of  cells  and  can 
replicate with high efficiency using the host’s replication machinery they are 
prime candidates for the expression and delivery of genes. The adenovirus 
infectious  cycle  can  be  clearly  divided  into  two  phases.  The  first or  early 
phase covers the entry of the virus into the host cell and the passage of viral 
genome to the nucleus followed by the selective transcription and translation 
of the early genes. Those early events modulate the function of the cell to 
initiate the transcription and translation of the late genes in the second or late 
phase of the adenoviral infection cycle. Adenoviral vectors are based on the 
adenovirus type five backbone in which an expression cassette containing 
up to 6.5 kb foreign DNA can be introduced in place of the early region 1 (E1) 
and/or early region 3 (E3) genes. Viruses in which E1 has been deleted are 
defective  for  replication  and  have  to  be  propagated  in  the  human  293 
complementation cells, providing the E1 products in trans. Viruses defective 
in  E3  loose  their  E3  gene-mediated  defense  mechanisms  against  host 
immune  responses  (81).  The  Adenovirus  2D6  (Ad-2D6)  used  in  our  study, 
obtained via Prof. Eric F. Johnson (The Scripps Research Institute, La Jolla, 
CA) was created by homologous recombination in Escherichia coli BJ5183 
between a shuttle vector containing the cDNA for CYP2D6 and pAdE1
-E3
- 
and was therefore defective in both, its replication via deletion of E1 and its   39
immunosuppressive functions by deletion of E3 (82). One of the adenoviruses 
used  as  control  (Ad-C)  was  the  empty  Adenovirus  vector  used  for  the 
production of Ad-2D6 whereas the other control adenovirus (Ad-GFP) that 
expresses the green fluorescent protein (GFP) instead of CYP2D6 was kindly 
provided by D.J. von Seggern (The Scripps Research Institute, La Jolla, CA). 
8.2 Working hypothesis 
By  the  use  of  a  newly  designed  animal  model  we  wanted  to  see  if  viral 
inflammation  caused  by  a  liver-tropic  adenovirus  conferring  molecular 
mimicry to a naturally occurring autoantigen in the liver can break tolerance 
and induce autoimmunity. Therefore we used the naturally occurring human 
CYP2D6  autoantigen  as  target  antigen.  The  wild-type  FVB/N  mice, 
expressing  only  the  mouse  CYP2D6  homologues  and  the  humanized 
CYP2D6  mice,  expressing  the  mouse  homologues  as  well  as  the  human 
CYP2D6 under the control of its own promoter as a self-antigen in the liver 
were  chosen  as  model  system.  Those  mice  are  under  normal  conditions 
tolerant/ignorant to the transgenic/self CYP2D6 antigens. In order to break 
natural tolerance to the transgenic/self CYP2D6 antigen by viral infection we 
choose an adenovirus vector expressing the human CYP2D6 gene that is 
replication deficient and stripped from its immunosuppressive functions due 
to a deletion of the adenoviral E1 and E3 genes. The use of a liver-tropic 
adenovirus ensured a high expression rate of the triggering antigen in the 
liver  as  well as  potent  activation of  the  immune  system by  viral  infection. 
Thus, infection with Ad-2D6 causes local non-specific activation of the innate 
immune  system  and  possibly  direct  damage  to  hepatocytes  leading  to 
chemokine  and cytokine  release  that  attract  and  activate  lymphocytes  via 
bystander  activation.  In  parallel,  infection  with  Ad-2D6  leads  to  high 
expression  of  viral  CYP2D6  in  the  liver  that  activate  the  antigen-specific 
adaptive  immune  response  and  leads  to  expansion  of  both  viral  and  self 
CYP2D6-specific lymphocytes via molecular identity in case of the human 
CYP2D6 or molecular mimicry in case of the mouse CYP2Ds isoenzymes. 
Activated and expanded antigen-specific effector cells cause destruction of   40
virus-infected altered self cells as well as self cells. After all virus and viral-
infected cells are deleted activated lymphocytes migrate deeper into the liver 
parenchyma  and  cause  further  damage  to  hepatocytes  expressing  self 
CYP2D6  (CYP2D6  mice)  as  well  as  CYP2Ds  (FVB/N)  resulting  in  clinically 
overt liver damage (see figure: Figure 4). 
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Figure 4: Working hypothesis for breaking self-tolerance to liver autoantigens by viral 
infection 
(1)  Wild-type  FVB/N  as  well  as  CYP2D6  mice  are  tolerant/ignorant  to  their  self  CYP2D 
antigens. (2) Ad-2D6 infection  causes local non-specific inflammation  and  possibly direct 
damage to hepatocytes. Chemokines and cytokines attract and activate lymphocytes in a 
non-specific manner (bystander activation). In parallel, infection with Ad-2D6 leads to high 
expression of viral CYP2D6. (3) Specific anti-viral CYP2D6 lymphocytes (B and T cells) are 
activated and expanded reacting against both human CYP2D6 (molecular identity) and self 
CYP2Ds (molecular mimicry). Effector lymphocytes destroy viral-infected altered self cells as 
well as self cells. (4) Later, activated lymphocytes migrate deeper into the liver parenchyma 
and  cause  further  damage  to  hepatocytes  expressing  self  CYP2D6  as  well  as  CYP2Ds 
resulting in clinically overt liver damage.   41
9  Results 
9.1 Introduction  of  the  CYP2D6  mouse  model  for 
autoimmune hepatitis 
As  described  previously  the wild-type FVB/N  mice,  expressing  the  mouse 
CYP2Ds  and  the  humanized  CYP2D6  mice  (see  chapter  The  CYP2D6 
humanized mice), expressing the mouse homologues as well as the human 
CYP2D6 under the control of its own promoter as a self-antigen in the liver 
were  chosen  as  animal  models.  An  adenovirus  expressing  the  human 
CYP2D6 (see chapter Adenoviruses) was used to break self-tolerance to the 
transgenic  CYP2D6  (via  molecular  identity)  and  potentially  to  the  mouse 
CYP2Ds  (via  molecular  mimicry)  by  viral  infection  (see  chapter:  Working 
hypothesis).  Infection  with  Ad-2D6  resulted  in  two  distinct  phases  of  liver 
damage,  an  acute,  antiviral  phase  characterized  by  transient  elevation  of 
serum values related to liver damage and minor cellular infiltrations, followed 
by  a  persistent,  autoimmune-mediated  phase  characterized  by  massive 
hepatocellular  damage,  strong  cellular  infiltration  and  the  development  of 
subcapsular  fibrosis.  Infection  with  Ad-GFP  resulted  in  only  acute  phase 
hepatitis but no long-lasting liver damage. 
9.1.1 Route of infection 
To assess the difference between intra-peritoneal (i.p.) and intra venous (i.v.) 
infections CYP2D6 mice were infected with 1 x 10
10 particles of Ad-GFP. The 
livers  were  removed  at  day  seven  post-infection  and  examined  under  a 
fluorescence  microscope.  After  i.p.  infection  with  Ad-GFP  most  GFP 
expressing cells in the liver were found in subcapsular areas, whereas i.v. 
infection led to GFP expressing cells located within the liver (Figure 5). Since 
the purpose of our model was to break tolerance to a self-antigen, we were 
interested  in  having  as  many  cells  expressing  the  adenoviral  delivered 
proteins as possible. Hence, we decided to choose a combination of i.p. and 
i.v. infections for further analysis.   42
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Figure 5: GFP expression in the liver after different route of Ad-GFP infection 
Expression of GFP in liver sections of CYP2D6 mice at day seven after i.p. or i.v. infection 
with Ad-GFP. 
9.1.2 Protein expression in the liver 
To  assess  the  kinetics  of  protein  expression  in  the  liver  after  adenovirus 
infection wild-type FVB/N and transgenic CYP2D6 mice were infected with 2 
x 10
10 particles (1 x 10
10 particles i.p. and i.v) of adenovirus expressing GFP. 
The  mice  were  sacrificed  and  the  liver  removed  at  different  days  after 
infection.  Examination  under  a  fluorescence  microscope  revealed  GFP-
expressing  cells  in  the  liver as  early as  one  day  after  infection.  Strongest 
expression of GFP was detected at day seven post-infection and after 14 
days only very few remaining cells still produced low levels of the adenovirus 
delivered  GFP  protein  (see  Figure  6).  Similar  expression  kinetics  for  GFP 
were detected in Ad-GFP-infected wild-type FVB/N mice (not depicted). 
Day 0 Day 14 Day 7 Day 3 Day 1
 
Figure 6: Expression of GFP after AD-GFP infection 
Expression of GFP in liver sections at several times after infection of CYP2D6 mice with Ad-
GFP.   43
9.1.3 Infection  of  mice  with  adenovirus  results  in  transient 
hepatic damage 
In patients, abnormal serum values related to liver damage are often the first 
clinical  signs  for  ALD.  However,  abnormal  serum  values  related  to  liver 
damage are not exclusive to ALD but can be seen in a wide range of acute 
and  chronic  diseases  targeting  the  liver  as  well  as  after  intake  of  several 
drugs.  On  the  other  hand,  patients  with  chronic  ALD  not  always  show 
increased serum values. Depending on the enzyme activity measured, it can 
be distinguished if the disease causing the abnormal values is more related 
to  hepatocyte  injury  or  biliary  obstruction.  Increased  alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) activities are 
more related to hepatocyte injury, whereas increased alkaline phosphatase 
(AP)  and  gamma  glutamyl  transpeptidase  (GGT)  activities  indicate  biliary 
obstruction. 
To find out more about the direct effect of adenovirus infection on the liver, 
FVB/N  and  CYP2D6  mice  were  infected  with  either  Ad-GFP  or  Ad-2D6, 
serum was collected at time points indicated and serum values related to 
liver damage were measured (Figure 7). All mice developed transient hepatic 
damage characterized by an elevation of ALT and AST serum levels. Values 
reached up to 250 U/liter of serum for ALT and up to 150 U/liter of serum for 
AST. However, this elevation appeared only transiently from week one to five 
after  infection  and  serum  aminotransferase  levels  regressed  to  normal, 
preinfection levels around week six after Ad-2D6 or Ad-GFP infection (Figure 
7 (A)). Mice that have been infected with Ad-2D6 showed a nonsignificant 
tendency  toward  an  earlier  increase  in  ALT  and  AST  compared  to  mice 
infected  with  Ad-GFP.  However,  statistical evaluation of  the augmentation 
over  time  after  infection  revealed  that  there  was  no  significant  difference 
between  mice  that  have  been  infected  with  Ad-2D6  and  Ad-GFP  and 
between FVB/N and CYP2D6 mice. In addition to the hepatic damage marker 
ALT  and  AST,  we  measured  AP  and  GGT  in  order  to  see  if  adenovirus 
infection caused biliary obstruction in our mice. We found a minor increase in 
AP at weeks one and two after infection with Ad-2D6 but not with Ad-GFP   44
and no acute or persistent elevation of GGT levels (Figure 7 (B)). As observed 
for ALT and AST, the elevation in AP was only transient and no significant 
increase was found at week four or later, indicating that no persistent biliary 
obstruction occurred after infection of mice with either Ad-2D6 or Ad-GFP. In 
summary,  these  data  indicate  that  adenovirus  infection  by  itself  results  in 
acute but transient hepatocellular damage. 
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Figure  7:  Serum  enzyme  activity  tests  related  to  liver  damage  after  adenovirus 
infection 
(A) Serum levels of ALT and AST in wild-type FVB/N (open symbols) and humanized CYP2D6 
(closed symbols) mice at time points indicated after infection with Ad-GFP (triangle) or Ad-
2D6 (circle). Statistical evaluation (t test) revealed no significant differences in AST and ALT 
augmentation curves over time between Ad-GFP- and Ad-2D6-infected mice and between 
FVB/N and CYP2D6 mice (n = mice per group). (B) Serum levels of AP and GGT in wild-type 
FVB/N (open symbols) and humanized CYP2D6 (closed symbols) mice infected with Ad-GFP 
(triangle)  or  Ad-2D6  (circle)  at  time  points  indicated  post-infection  (n  =  mice  per  group). 
Statistical  evaluation (t test) revealed only at  week one and two significant differences in 
serum AP compared with  preinfection levels and  between Ad-2D6- and Ad-GFP-infected 
mice. Data are mean ± SD.   45
9.1.4 Infection  with  Ad-2D6  results  in  severe  and  persistent 
liver damage 
To evaluate if autoimmune-mediated liver damage can be triggered by viral 
infections, we infected wild-type FVB/N and humanized CYP2D6 mice either 
with 2 x 10
10 particles of Ad-2D6 or with 2 x 10
10 particles of Ad-GFP. Mice 
were  sacrificed  and  livers  removed  and  analyzed  at  several  times  after 
infection. In contrast to the infection of mice with the control virus Ad-GFP, 
Ad-2D6  infection  resulted  in  severe  and  long-lasting  liver  damage 
characterized  by  morphological  alterations  of  the  liver,  massive  infiltration 
and fibrosis. 
9.1.4.1 Morphological signs of liver damage after Ad-2D6 infection 
Morphologically,  livers  of  Ad-2D6-infected  mice  showed  several  features 
characteristic for liver damage associated with autoimmune-mediated liver 
disease and/or chronic viral hepatitis that could already be assessed while 
the liver was removed. The most obvious morphological changes included 
aberrancies in size and shape of the liver, fusion of the individual liver lobes, 
hyperplasic nodules and capsular fibrosis. Importantly, these morphological 
alterations only occurred after Ad-2D6 infection and not after Ad-GFP control 
virus infection (Figure 8). 
To semiquantitatively evaluate the morphological appearance we defined a 
liver damage score (LDS) based on liver alterations found after adenovirus 
infections (Table 1). Evaluation of LDS was determined by visual examination 
of  the  freshly  harvested  liver  after  sacrificing  the  mice.  Pictures  of 
representative  livers  of  LDS  0  (Ad-GFP-infected)  and  LDS  5  (Ad-2D6-
infected) are depicted in Figure 8 (B).   46
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Figure 8: Morphology of the livers after adenovirus infection 
(A) Exposed livers in the abdomen of CYP2D6 mice infected with either Ad-GFP (left side) or 
Ad-2D6  (right  side)  at  week  eight  after  infection.  (B)  Paraformaldehyde-fixed  livers  of 
CYP2D6 mice infected with either Ad-GFP (left side) or Ad-2D6 (right side) at week eight 
after infection. Livers are either shown from the anterior side (upper panel) or the visceral 
side (lower panel). The Liver damage score for these representative livers are shown as LDS 
0 (Ad-GFP-infected liver) and LDS 5 (Ad-2D6-infected liver). 
Liver damage 
score (LDS) 
Fused liver 
lobes 
Size/shape  Cirrhosis  Hyperplasic 
nodules 
Capsular 
fibrosis 
0  No  Regular  No  No  No 
1  Partial  Regular  No  No  No 
2  Partial  Swollen  No  No  No 
3  Complete  Swollen  Starting  Some  Visible 
4  Complete  Clump  Strong  Many  Visible 
5  Complete  Clump  Strong  Many  Strong 
 
Table 1: LDS definition to assess morphological liver alterations by visual examination 
LDS was used to determine the morphological liver alterations of FVB/N and 
CYP2D6 mice infected with either Ad-GFP or Ad-2D6 over a time period of 
45  weeks  (Figure  9).  Importantly,  LDS  was  persistently  elevated  in  both 
FVB/N  and  CYP2D6  mice  after  infection  with  Ad-2D6  only  and  almost no   47
morphological signs of liver damage were detected in mice infected with Ad-
GFP. Statistical evaluation revealed that the LDS was significantly different 
between Ad-2D6- and Ad-GFP-infected FVB/N as well as CYP2D6 mice. 
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Figure 9: LDS at several time points after infection with adenovirus 
Livers of FVB/N (upper panel) and CYP2D6 (lower panel) mice were harvested at time points 
indicated after infection with either Ad-GFP (left side) or Ad-2D6 (right side) and LDS was 
determined by morphological examination. The mean LDS for each group is indicated by 
horizontal  lines.  Statistical  analysis  (Mann-Whitney  test)  revealed  significant  differences 
between Ad-2D6- and Ad-GFP-infected mice at the indicated time points: * = P < 0.01; ** = 
P < 0.05. 
Interestingly, >50% of wild-type FVB/N mice showed the first morphological 
signs of liver damage already one week after infection with Ad-2D6 whereas 
in  transgenic  CYP2D6  mice  obvious  signs  of  liver  damage  was  first 
detectable after two weeks of infection with Ad-2D6. However, no significant 
difference  in  the  overall  LDS  between  wild-type  and  transgenic  mice  was 
detected at later times. These data demonstrate that the viral expression of   48
CYP2D6  resulted  in  persistent  liver  damage  although  only  a  transient 
elevation  of  serum  markers  related  to  liver  damage  could  be  found  after 
adenovirus infection of FVB/N and CYP2D6 mice. 
9.1.4.2 Ad-2D6-infected mice show massive infiltration 
An important diagnostic feature in human ALD is histological examinations of 
liver biopsies. To evaluate the infiltrations after adenovirus infection, FVB/N 
and  CYP2D6  mouse  livers  were  harvested  at  various  time  points  after 
infection  with  Ad-GFP  or  Ad-2D6  and  liver  sections  were  stained  for 
histological analysis. An early inflammatory phenotype was seen in FVB/N 
and  CYP2D6  mice  after  infection  with  both,  Ad-GFP  and  Ad-2D6  virus 
(Figure 10 (top row)). However, this initial acute hepatitis was only transient 
and likely caused by the direct antiviral immune response. Importantly, only 
infection  with  Ad-2D6,  but  not  Ad-GFP,  resulted  in  a  massive  increase  in 
inflammation and liver cell destruction in both FVB/N and CYP2D6 mice at 
later time points after infection. Already at week four after infection Ad-GFP-
infected mice showed a reduced amount of cellular infiltrates compared to 
Ad-2D6-infected  mice  and  no  focal  necrosis,  whereas  in  Ad-2D6-infected 
mice  the  areas  of  focal  necrosis  and  cellular  infiltrations  were  becoming 
larger and increased in numbers (Figure 10 (middle row)). After eight weeks 
FVB/N  and  CYP2D6  mice  infected  with  Ad-GFP  showed  nearly  no  focal 
points  of  lymphocyte  accumulation  and  only  some  scattered  lymphocytes 
were still detectable. Mice infected with Ad-2D6 however, showed a massive 
increase  in  inflammation  and  liver  cell destruction.  Interface  hepatitis  with 
extensive  infiltrates  in  the  periportal  and  parenchymal  regions  could  be 
detected and the areas of focal necrosis were growing larger and confluent 
(Figure 10 (bottom row)).   49
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Figure 10: Hepatic necrosis and massive cellular infiltrations after Ad-2D6 infection 
Hematoxylin and eosin staining of liver sections obtained from FVB/N (left side) and CYP2D6 
(right side) mice one, four and eight weeks after infection with Ad-GFP or Ad-2D6.  
Similar to the LDS we defined a histological infiltration score (HIS) based on 
liver  infiltrations  found  after  adenovirus  infections  to  semiquantitatively 
evaluate  the  infiltration  in  our  mice  (Table  2).  Evaluation  of  HIS  was 
determined by blinded analysis of complete liver sections obtained from mice 
infected with either Ad-GFP or Ad-2D6. 
Histological 
infiltration score (HIS) 
Description of found infiltration 
0  No visible infiltration 
1  Few focal infiltrates 
2  Numerous scattered focal infiltrates 
3 
Few  large  clusters  of  infiltrating  cells  (perivascular  or 
subcapsular) 
4 
Numerous  large  clusters  of  infiltrating  cells  occupying 
>50% of portal tracts or central veins 
5  Confluent periportal infiltrates 
Table  2:  HIS  for  blinded  evaluation  of  infiltrations  in  mouse  livers  after  adenovirus 
infection   50
HIS  was  used  to  determine  liver  infiltrations  of  FVB/N  and  CYP2D6  mice 
infected with either Ad-GFP or Ad-2D6 at week one, four and eight post-
infection (Figure 11). Importantly, persistently high HIS in FVB/N and CYP2D6 
mice was only detected after Ad-2D6 infection, whereas the acute elevated 
HIS one week after Ad-GFP infection reverted to almost pre-infection scores 
after  eight  weeks  of  infection.  Interestingly,  in  FVB/N  mice,  a  significant 
difference in HIS after Ad-GFP and Ad-2D6 infection was already detectable 
from  week  four  after  infection,  suggesting  an  accelerated  liver  damage  in 
wild-type FVB/N mice compared to humanized CYP2D6 mice. 
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Figure 11: HIS at several time points after infection with adenovirus 
Liver sections of FVB/N (open bars) and CYP2D6 (filled bars) mice infected with Ad-GFP (left 
side) or Ad-2D6 (right side) were analyzed in a blinded fashion at time points indicated using 
HIS.  The  presented  data  are  mean  HIS  ±  SEM.  Statistical  analysis  (Mann-Whitney  test) 
revealed  significant  differences  between  mice  infected  with  Ad-GFP  and  Ad-2D6  at  the 
indicated times after infection: * = P < 0.05. The number of individual mouse livers analyzed 
per experimental group is indicated at the bottom of each bar. 
To determine what cell types are infiltrating the livers of FVB/N and CYP2D6 
mice after Ad-2D6 infection immunohistochemical analysis of liver sections 
obtained from mice two weeks after Ad-2D6 infection were performed (Figure 
12). Cellular infiltrates consisted predominantly of B cells (B220
+ cells), CD4
+ 
T cells and macrophages (F4/80
+ cells) whereas only a few CD8
+ T cells were 
found.  In  keeping  with  our  initial  observation  that  wild-type  FVB/N  mice 
showed higher HIS compared to humanized CYP2D6 mice four weeks after 
Ad-2D6 infection (Figure 11), we found that FVB/N had more rapid cellular 
infiltration  compared  to  CYP2D6  mice.  Liver  sections  of  Ad-2D6-infected   51
FVB/N  mice  two  weeks  post-infection  showed  already  cellular  infiltrations 
similar to liver sections of CYP2D6 mice four and eight weeks after Ad-2D6 
infection,  whereas  liver  sections  of  Ad-2D6-infected  CYP2D6  mice  two 
weeks after infection showed only minor infiltrates. 
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Figure 12: Immunohistochemical analysis of liver sections after infection with Ad-2D6 
Liver sections obtained from FVB/N (upper panel) and CYP2D6 (lower panel) two weeks after 
Ad-2D6 infection stained for B cells (B220), CD4
+ T cells (CD4), macrophages (F4/80) and 
CD8
+ T cells (CD8). 
9.1.4.3 Ad-2D6-infected  mice  show  development  of  subcapsular 
fibrosis 
Extensive and long-lasting liver damage as in human ALD or chronic hepatitis 
in general leads to the development of fibrosis and often to progression from 
fibrosis to cirrhosis, a more severe and mostly irreversible form of fibrosis in 
the  liver.  Fibrosis  is  characterized  by  an  increase  in  extracellular  matrix 
protein production and a shift to collagen I as major component of it. To 
evaluate liver fibrosis after adenovirus infection, FVB/N and CYP2D6 mice 
were infected with Ad-GFP or Ad-2D6 and liver sections obtained at various 
time points after infection were stained for collagen fibers by Sirius red or 
fluorescence immunohistochemistry staining for collagen I (Figure 13). Tissue 
sections covering the entire liver form FVB/N and CYP2D6 mice after Ad-  52
GFP and Ad-2D6 infection were analyzed by Sirius red staining at several 
time  points  after  infection  (Figure  13  (A)).  Importantly,  an  increase  in 
subcapsular liver fibrosis over time was detected exclusively after Ad-2D6 
infection in FVB/N and CYP2D6 mice, whereas no difference in collagen I 
deposition  over  time  could  be  found  after Ad-GFP  control  virus  infection. 
Interestingly, the development of subcapsular fibrosis was accelerated and 
more pronounced in wild-type FVB/N mice compared to transgenic CYP2D6 
mice supporting our previous findings of an accelerated liver damage in wild-
type FVB/N mice. For a better visualization of the predominantly subcapsular 
and  interlobular  fibrosis,  we  performed  a  reconstruction  of  a  liver  section 
stained  by  fluorescence immunohistochemistry  for  collagen  I  covering  the 
entire  liver  of a  representative  CYP2D6  mouse  eight  weeks  after  infection 
with  Ad-2D6  (Figure  13  (B)  (left  side)).  The  figure  shows  the  massive 
subcapsular  fibrosis  and  the  interlobular  collagen  I  deposits  that  glue  the 
individual lobes (including the left and right medial as well as the left lateral 
lobes)  together.  Confirming  our  results  obtained  by  Sirius  red  staining  no 
significant  collagen  I  deposits  were  found  in  Ad-GFP-infected  mice. 
Costaining for B cells (B220
+ cells) showed that many cellular infiltrates are 
located in close proximity to the subcapsular collagen I deposits (Figure 13 
(B) (right side)). In summary, these data indicate that infection with Ad-2D6 
but not with Ad-GFP can induce a persistent liver damage in both, the wild-
type  FVB/N  as  well  as  the  humanized  CYP2D6  mice.  Additionally,  the 
findings that wild-type FVB/N mice showed accelerated liver damage, more 
rapid  cellular  infiltration  and  an  accelerated  and  more  pronounced 
development of subcapsular fibrosis then humanized CYP2D6 mice indicates 
the existence of partial tolerance in CYP2D6 mice.   53
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Figure 13: Subcapsular fibrosis after infection of mice with Ad-2D6 but not Ad-GFP 
(A) Sirius red staining of collagen fibers in the subcapsular region of the liver of FVB/N (left 
side)  and  CYP2D6  (right  side)  mice  at  time  points  indicated  after  Ad-GFP  or  Ad-2D6 
infection. Tissue sections covering the entire liver from three to five mice per experimental 
group were analyzed and a representative picture of the subcapsular region is displayed for 
each time point. (B) Reconstruction of a large section of a CYP2D6 mouse liver eight week 
after infection with Ad-2D6 including the left medial (LM) and right medial (RM) lobes and the 
left lateral (LL) lobe, stained for collagen I (green) by fluorescence immunohistochemistry. 
(Inset)  Reconstruction  of  the  left  lateral  lobe  of  a  CYP2D6  mouse  liver  eight  weeks  after 
infection with Ad-GFP. Regions 1 – 4 are shown at a higher magnification. In addition to 
staining for collagen I (green), staining for B cells (B220
+, red) was overlaid. Region 1 and 2 
show B cells entrapped in pockets within the collagen I deposits in the subcapsular region of 
the liver. Region 3 and 4 show areas where two or three individual liver lobes are joined by 
collagen I fibers.   54
9.2 Pathogenic  mechanism  in  the  CYP2D6  mouse 
model for autoimmune hepatitis 
Since we could show that virally delivered CYP2D6 protein can induce long-
lasting  liver  damage  characterized  by  persistent  hepatic  infiltrates  and 
necrosis  as  well  as  the  development  of  subcapsular  fibrosis  in  wild-type 
FVB/N  and  humanized  CYP2D6  mice,  we  were  interested  on  the 
immunological  mechanisms  responsible  for  the  observed  liver  damage. 
Because  infection  with  a  control  virus  (Ad-GFP)  resulted  in  only  transient 
hepatitis but no long-lasting liver damage, we could assume that the virally 
delivered  human  CYP2D6  protein  was  responsible  for  the  persistent  liver 
damage  found  in  our  mice  and  that  this  damage  was  likely  to  be 
autoimmune-mediated. However, in order to prove that the persistent liver 
damage  found  in  our  mice  was  autoimmune-mediated  we  intended  to 
demonstrate breaking of tolerance to liver-specific self-antigens by Ad-2D6 
infection. Since the hallmark of human AIH type 2 are LKM-1 autoantibodies 
targeting the CYP2D6 protein we first investigated if the B cell tolerance in 
our mice is broken after Ad-2D6 infection. Infection with Ad-2D6 but not with 
Ad-GFP resulted in breaking of B cell tolerance and generation of LKM-1 like 
antibodies  in  wild-type  FVB/N  as  well  as  humanized  CYP2D6  mice.  In 
addition, viral infection was essential for persistent liver damage but not for 
breaking of B cell tolerance and autoantibody production. Lastly, infection 
with Ad-2D6 but not with Ad-GFP resulted in breaking of T cell tolerance and 
CYP2D6-specific IFN-  production from CD4
+ and CD8
+ T cells. 
9.2.1 B cell  tolerance to liver-specific self antigen is  broken 
after Ad-2D6 infection 
Breaking of  B cell  tolerance  leads  to  activation  and differentiation  of  self-
reactive B cells that then will produce and secrete autoantibodies specific for 
the self-antigen. In order to investigate if Ad-2D6 infection leads to a loss of 
B cell tolerance and production of autoantibodies in wild-type FVB/N and 
humanized  CYP2D6  mice  we  collected  serum  of  Ad-GFP-  or  Ad-2D6-  55
infected mice at various times after infection and determined the serum titer 
of anti-human CYP2D6 antibodies by ELISA. Anti-CYP2D6 antibodies of the 
IgM isotype were found to a similar extent in FVB/N and CYP2D6 mice after 
infection  with  Ad-2D6  and  reached  a  maximum  titer  of  500-900  between 
weeks  two  and  four  after  infection.  No  detectable  anti-CYP2D6  IgM 
antibodies could be found after Ad-GFP infection in FVB/N or CYP2D6 mice 
(Figure  14  (left  side)).  Importantly,  anti-CYP2D6  IgG  antibodies  could  be 
detected at high titers in FVB/N and CYP2D6 mice after Ad-2D6 infection. In 
contrast,  only  very  low  titers of  CYP2D6-specific  IgG  antibodies  could  be 
detected  after  Ad-GFP  infection  (Figure 14  (right  side)).  Interestingly,  anti-
CYP2D6 IgG antibodies reached higher titers in Ad-2D6-infected wild-type 
FVB/N mice then in humanized CYP2D6 mice.  
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Figure 14: Generation of anti-CYP2D6-specific antibodies after Ad-2D6 infection 
Serum titers of IgM (left side) and IgG (right side) anti-CYP2D6 antibodies in FVB/N (upper 
panel) and CYP2D6 (lower panel) mice at time points indicated after Ad-GFP (open symbols) 
or Ad-2D6 (closed symbols) infection. Sera dilutions with values of three standard deviations 
above the mean value of negative controls were considered positive. Data are mean ± SEM.   56
Anti-CYP2D6  antibodies  of  the  IgE  isotype  have  not  been  detected  after 
infection  with  Ad-GFP  or  Ad-2D6  in  both  FVB/N  and  CYP2D6  mice  (not 
depicted). 
The  anti-CYP2D6-specific  antibody  titer  detected  after  Ad-2D6  infection 
could either be produced by very potent antibody producing plasmacells or 
by a large number of CYP2D6-specific B cells. To investigate how many B 
cells produced the anti-CYP2D6-specific antibodies and analyze if there was 
a polyclonal activation of antibody producing plasmacells after Ad-GFP or 
Ad-2D6  infection  in  general,  FVB/N  and  CYP2D6  mice  were  infected  and 
spleens  were  removed  at  various  time  points  after  infection.  Splenocytes 
were  then  used  to  determine  the  number  of  total  Ig  and  anti-CYP2D6 
antibody producing plasmacells in a B cell ELISPOT assay (Figure 15 (A)). 
Analysis  of  the  ELISPOT  data  revealed  no  striking  differences  in  the 
frequency of  Ig-producing  cells of FVB/N  or  CYP2D6  mice  infected either 
with  Ad-GFP  or  Ad-2D6  (Figure 15  (B)  (upper  panel)).  Importantly,  B  cells 
secreting  anti-CYP2D6-specific  antibodies  were  exclusively  found  in  Ad-
2D6-infected mice (Figure 15 (B) (lower panel)). The highest frequency of anti-
CYP2D6-specific  antibody-secreting  cells  was  found  at  week  four  after 
infection in both FVB/N and CYP2D6 mice, whereas wild-type mice showed 
a  higher  number  of  anti-CYP2D6-specific  antibody-secreting  cells  than 
CYP2D6  mice.  These  data  confirm  our  previous  finding  that  humanized 
CYP2D6  mice  did  not  reach  as  high  anti-CYP2D6  IgG  antibody  titers  as 
FVB/N mice. In addition, it further supports our previous findings indicating 
the existence of partial tolerance to human CYP2D6 in humanized CYP2D6 
mice, which is characterized by attenuated hepatocellular damage, less rapid 
cellular infiltration and less severe fibrosis when compared with less tolerant 
wild-type FVB/N mice   57
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Figure 15: Activation of CYP2D6-specific B cells after Ad-2D6 infection 
 (A) Picture of representative end-results of total IgG (upper panel) or CYP2D6-specific (lower 
panel)  spot-forming  assays.  Brownish  spots  indicate  the  reaction  of  enzyme-labeled 
secondary antibodies against secreted IgG and represent one antibody-secreting cell. (B) 
Quantification of total IgG (upper panel) and CYP2D6-specific IgG (lower panel) secreting 
cells per 10
6 splenocytes in FVB/N (left) and CYP2D6 (right) mice at time points indicated 
after infection with Ad-GFP (open bars) or Ad-2D6 (closed bars). ND = not detectable.  
One of the most reliable diagnostic tests for the characterization of ALD in 
humans  is  the  characterization  of  non-organ-specific  autoantibodies  in 
human  patients.  This  characterization  is  usually  performed  by  indirect 
immunofluorescence  staining  of  autoantibodies  on  rat  tissue  sections. 
Therefore  we  compared  the  staining  pattern  of  anti-CYP2D6  antibodies 
found in the sera of mice after Ad-2D6 infection with the staining pattern of 
sera  from  patients  with  various  autoimmune  liver  diseases  on  rat  liver 
sections (Figure 16). Sera from Ad-2D6-infected mice recognized a typical 
microsomal (ER/Golgi) pattern, characteristic for LKM-1 type autoantibodies 
present in sera from AIH type 2 patients. In contrast, sera from PBC or AIH 
type  1  patients  showed  a  clearly  distinguishable  mitochondrial  or  nuclear 
staining  pattern  typical  for  AMA  autoantibodies  found  in  PBC  or  ANA 
autoantibodies found in type 1 AIH patients.   58
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Figure 16: Staining pattern of anti-CYP2D6 antibodies after Ad-2D6 infection 
Representative pictures of rat liver sections stained with sera from Ad-2D6-infected FVB/N 
and CYP2D6 mice, AIH type 1, AIH type 2 and PBC patients followed by appropriate staining 
with a fluorescence-conjugated secondary antibody. 
In summary, we could show that infection with Ad-2D6 resulted in a loss of B 
cell tolerance to the virally delivered self-protein CYP2D6 and that Ad-2D6-
infecteed FVB/N as well as CYP2D6 mice produced LKM-1 like antibodies. In 
addition,  we  could  confirm  our  previous  results  that  indicated  a  partial 
tolerance in humanized CYP2D6 resulting in a lower number anti-CYP2D6-
specific antibody-secreting cells and lower anti-CYP2D6 IgG antibody titers 
compared to wild-type FVB/N mice. 
9.2.2 Anti-CYP2D6  antibodies  in  Ad-2D6-infected  mice  and 
sera  from  AIH-2  patients  recognize  an  identical 
immunodominant epitope 
LKM-1 autoantibodies are the hallmark of AIH type 2. It could be shown that 
such autoantibodies recognize an immunodominant epitope of CYP2D6 in 
most patients with AIH type 2. To further analyze the antibodies found in Ad-
2D6-infected  mice  we  mapped  the  dominant  B  cell  epitopes  using  the 
SPOTs  technology.  To  this  end,  staggered  peptides  covering  the  entire 
human CYP2D6 sequence were covalently linked to a nylon membrane. The 
SPOTs membranes have been incubated with sera obtained from Ad-2D6-
infected mice overnight and reactivity was visualized by the incubation with 
enzyme-labeled  secondary  antibodies  against  mouse  IgG  (Figure  17  (A)). 
Linear epitopes reacting with the sera were clearly visible and could easily be 
quantified. To compare the recognized B cell epitopes of Ad-2D6-infected 
mice,  AIH  type  1  and  AIH  type  2  patients  the  serum  reactivity  profile  to   59
SPOTs peptides was quantified and illustrated in a consecutive way (Figure 
17  (B)  and  (C)).  Interestingly,  sera  from  all  Ad-2D6-infected  FVB/N  and 
CYP2D6  mice  predominantly  reacted  to a  cluster  of  overlapping  peptides 
within the core amino acid (aa) sequence WDPAQPPRD (CYP2D6 aa 262-
270).  It  has  been  shown  that  LKM-1  autoantibodies  of  AIH-2  patients 
predominantly recognize the immunodominant linear CYP2D6254-271 sequence 
and indeed, all of the AIH-2 patient sera we tested reacted to the same core 
aa  sequence  as  the  sera  of  Ad-2D6-infected  mice.  In  contrast,  sera  from 
patients  with  other  ALD,  like  AIH  type  1  or  PBC,  did  not  recognize  the 
immunodominant  CYP2D6  B  cell  epitope.  As  for  AIH-2  patients  other 
epitopes were recognized by the sera of Ad-2D6-infected mice, however, to 
a much lesser extent and with some variation between individual mice. We 
found  that  the  pattern  of  epitope  recognition  was  mostly  overlapping 
between sera from Ad-2D6-infected mice and patients with AIH type 2, but 
not with the sera of patients with other ALD. In summary, we found that the 
Ad-2D6-induced breakdown of B cell tolerance to human CYP2D6 in wild-
type  FVB/N  and  humanized  CYP2D6  mice  resulted  in  an  autoimmune 
reactivity that is very similar to that found in AIH type 2 patients. In addition, 
we could demonstrate that the autoimmune reactivity after Ad-2D6 infection 
is  characterized  by  the  presence  of  autoantibodies  recognizing  an 
immunodominant epitope identical to that recognized by sera from patients 
with type 2 AIH.   60
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Figure  17:  Mouse  anti-CYP2D6  and  sera  of  AIH-2  patients  recognize  the  identical 
immunodominant CYP2D6 epitope 
 (A) SPOTs membrane containing staggered peptides of 12 aa in length covering the entire 
497 aa of the human CYP2D6 molecule. This representing membrane was developed with 
serum  of  an  Ad-2D6-infected  CYP2D6  mouse.  Numbers  indicate  the  position  within  the 
CYP2D6  sequence  of  the  first  aa  of  the  first  peptide  spot  in  each  horizontal  lane.  (B) 
Quantification  of  the  serum  reactivity  profile  to  SPOTs  peptides.  Representative 
quantification of serum samples of an Ad-2D6-infected FVB/N mouse, an Ad-2D6-infected 
CYP2D6 mouse, an AIH-2 patient and an AIH-1 patient are depicted. Numbers indicate the 
aa position within the human CYP2D6 sequence. (C) For an overview of the epitope profile, 
the human CYP2D6 sequence was divided into 20 25-aa long sections, as indicated at the 
top of each column. Signal intensities of sera from  Ad-2D6-infected CYP2D6 and FVB/N 
mice, patients with AIH-2, and patients with other ALD such as AIH-1 or PBC are indicated 
in red (strong), orange (medium), gray (low) and white (no reactivity).   61
9.2.3 Virus  infection  is  essential  for  persistent  liver  damage 
but not autoantibody production 
To analyze the importance of viral delivery of the human CYP2D6 to the liver 
and  the  resulting  acute  inflammation  mice  were  infected  with  Ad-2D6  or 
immunized with human recombinant CYP2D6 alone or in combination with 
Poly-IC (i.v.), CpG (i.v.), IFA (s.c.) or CFA (s.c.). Anti-CYP2D6 antibody titers 
as  well  as  LDS  as  marker  for  persistent  liver  damage  were  analyzed. 
Interestingly,  although  all  immunization  strategies  resulted  in  low  anti-
CYP2D6 antibody titers (Figure 18) only mice infected with Ad-2D6 showed 
persistent  liver  damage  reflected  by  increased  LDS  at  12  weeks  after 
infection. 
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Figure 18: Antibody titer after different immunization strategies 
Serum titers of IgG anti-CYP2D6 antibodies in FVB/N (left side) and CYP2D6 (right side) mice 
at 12 weeks post-treatment with 10 µg human recombinant CY2D6 (hrec CYP2D&) alone, in 
combination  with  pIC,  CpG,  IFA  or  CFA  or  12  weeks  post-infection  with  Ad-2D6.  Sera 
dilutions with values of three standard deviations above the mean value of negative controls 
were considered positive. Data are mean ± SEM. i.v. = intra venous; s.c. = sub cutan 
In particular, immunization with recombinant human CYP2D6 in combination 
with CFA (s.c.) resulted in a antibody titer similar to that found after Ad-2D6   62
infection but did not result in autoimmune liver disease. These data indicate 
that  the  generation  of  anti-CYP2D6  antibodies  alone  is  not  sufficient  to 
induce  autoimmune  liver  damage  in  our  mice.  In  addition,  these  data 
underline  the  importance  of  the  liver-tropic  viral  infection  in  initiating 
autoimmune-mediated  liver  damage  in  our  mouse  model  and  suggest  an 
important  role  for  environmental  factors  like  viral  inflammation  as  trigger 
mechanism for autoimmunity. 
9.2.4 T  cell  tolerance  to  liver-specific  self  antigen  is  broken 
after Ad-2D6 infection 
Since we could show that infection of FVB/N and CYP2D6 mice with Ad-2D6 
leads to a loss of B cell tolerance as well as the production of anti-CYP2D6 
antibodies of the IgG isotype and antibody class switching requires specific 
CD4
+ T cell help we could assume that the T cell tolerance in our mice had to 
be  broken  as  well.  Breaking  of  T  cell  tolerance  leads  to  activation  and 
differentiation of self-reactive T cells. Upon activation T cells produce and 
release  cytokines  and  chemokines  that  attract  and  activate  other  immune 
cells and lead to differentiation and immunoglobulin class switch of activated 
B cells. Most importantly, they have direct pathogenic functions depending 
on  the  cytokines  released  and  on  the  T  cell  subset  activated.  Through 
collaboration  with  D.  Bogdanos  we  received  61  20-aa  long  peptides 
overlapping by 12 aa and spanning the entire human CYP2D6 sequence (63) 
(see  chapter  Appendix,  Figure  25).  These  peptides  have  been  previously 
used to demonstrate that MHC class I as well as MHC class II restricted T 
cell responses influence autoimmunity in AIH type 2 patients. We used those 
61  20mer  peptides  to  analyze  if  the  T  cell  tolerance  to  the  liver-specific 
CYP2D6 self antigen was broken in FVB/N mice after infection with Ad-GFP 
or Ad-2D6 by staining for intracellular cytokines (ICCS) produced by T cell 
subsets after ex vivo stimulation with those peptides. Therefore, FVB/N mice 
were  infected  with  Ad-GFP  or  Ad-2D6  and  splenocytes  as  well  as  liver 
lymphocytes  were  isolated  and  stained  for  surface  marker  to  distinguish 
between the T cell subsets as well as for intracellular IFN-  production to   63
analyze the activation status after overnight incubation with a pool of five 
20mer peptides. IFN-  production was measured by FACS analysis (Figure 
19). Only one peptide pool (peptides six to ten) was able to induce IFN-  
production in CD4
+ T cells whereas CD8
+ T cells were found to produce IFN-
  after stimulation with several peptide pools spanning the peptides 16 to 30 
of the human CYP2D6. Importantly, IFN-  producing T cells were only found 
after Ad-2D6 infection, but not after Ad-GFP infection. 
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Figure 19: Intracellular IFN-  staining after peptide pool stimulation in FVB/N mice 
(A)  Representative  dot  plots  of  liver  lymphocytes  of  an  Ad-GFP-  (left  side)  and  Ad-2D6-
infected (right side) FVB/N mouse five  weeks  post-infection stained for surface CD8  and 
intracellular  IFN- .  (B)  Surface  CD4  (left  side)  and  surface  CD8  (right  side)  staining  in 
combination with intracellular IFN  staining of liver lymphocytes of control virus (open bars) 
and Ad-2D6 (closed bars) FVB/N mice at week four post-infection after overnight stimulation 
with the corresponding peptide pool. 
To further evaluate the CYP2D6-specific T cell response in Ad-2D6-infected 
FVB/N  mice  those  peptide  pools  that  resulted  in  CYP2D6-specific  T  cell 
stimulation were split up and used for further ICCS (Figure 20). Interestingly,   64
CD4
+ T cells producing IFN-  were found only after stimulation with a single 
peptide  spanning  the  aa  41  to  60  of  the  human  CYP2D6,  whereas  five 
peptide  clusters  were  found  to  induce  IFN-   production  in  CD8
+  T  cells. 
Importantly,  none  of  these  peptides  induced  IFN-   production  in  CD4
+  or 
CD8
+  T  cells  if  the  mice  have  been  infected  with  Ad-GFP.  Interestingly, 
lymphocytes  isolated  from  the  liver  showed  an  approximately  three  times 
higher frequency of IFN-  producing T cells of both, the CD4
+ and CD8
+ T cell 
subsets compared to lymphocytes isolated from the spleen. This indicates 
that CYP2D6-specific CD4
+ and CD8
+ T cells either migrate and remain in the 
liver or that they extensively proliferate within the target organ. 
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Figure 20: Intracellular IFN-  staining after single peptide stimulation in FVB/N mice 
(A)  Surface  CD4  (left  side)  or  surface  CD8  (right  side)  and  intracellular  IFN   staining  of 
splenocytes of Ad-GFP (open bars) and Ad-2D6-infected (closed bars) FVB/N mice at week 
six  post-infection  after  overnight  stimulation  with  the  corresponding  peptide.  (B)  Surface 
CD4 (left side) or surface CD8 (right side) and intracellular IFN  staining of liver lymphocytes 
of Ad-GFP (open bars) and Ad-2D6-infected (closed bars) FVB/N mice at week six post-
infection after overnight stimulation with the corresponding peptide. 
To evaluate if T cell tolerance in CYP2D6 mice after infection with Ad-2D6 
was broken as it could be shown in FVB/N mice, CYP2D6 mice were infected 
with Ad-GFP or Ad-2D6 and splenocytes as well as liver lymphocytes were 
isolated  and  used  for  ICCS  after  overnight  stimulation  with  the  61  20mer   65
peptides  (Figure  21).  Interestingly,  no  IFN-   producing  T  cells  could  be 
detected after peptide pool stimulation of splenocytes isolated from CYP2D6 
mice. CYP2D6- specific CD8 T cells could only be found in liver lymphocytes 
(peptide pool 21-25). However, CD8
+ liver lymphocytes of Ad-2D6-infected 
CYP2D6 mice showed an approximately ten times lower frequency of IFN-  
producing T cells compared to CD8
+ liver lymphocytes of FVB/N mice. 
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Figure 21: Intracellular IFN-  staining after peptide pool stimulation in CYP2D6 mice 
(A)  Surface  CD4  (left  side)  or  surface  CD8  (right  side)  and  intracellular  IFN   staining  of 
splenocytes of control virus (open bars) and Ad-2D6-infected (closed bars) CYP2D6 mice at 
week four post-infection after overnight stimulation with the corresponding peptide pool. (B) 
Surface  CD4  (left  side)  or  surface  CD8  (right  side)  and  intracellular  IFN   staining  of  liver 
lymphocytes of control virus (open bars) and Ad-2D6-infected (closed bars) CYP2D6 mice at 
week four post-infection after overnight stimulation with the corresponding peptide. 
To  further  investigate  the  CYP2D6-specific  T  cell  response  in  Ad-2D6-
infected  CYP2D6  mice  further  ICCS  with  single  peptide  stimulation  was 
performed  (Figure  22).  No  significant  difference  in  the  frequency  of  IFN-  
producing T cells isolated from the spleen was found between control virus 
and Ad-2D6-infected CYP2D6 mice. Only the peptide numbers 21, 22, 28   66
and 29 were able to induce above 0.2% IFN-  producing CD8
+ T cells in liver 
lymphocytes of Ad-2D6-infected CYP2D6 mice. 
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Figure 22: Intracellular IFN-  staining after single peptide stimulation in CYP2D6 mice 
(A)  Surface  CD4  (left  side)  or  surface  CD8  (right  side)  and  intracellular  IFN   staining  of 
splenocytes of control virus (open bars) and Ad-2D6-infected (closed bars) CYP2D6 mice at 
week  four  post-infection  after  overnight  stimulation  with  the  corresponding  peptide.  (B) 
Surface  CD4  (left  side)  or  surface  CD8  (right  side)  and  intracellular  IFN   staining  of  liver 
lymphocytes of control virus (open bars) and Ad-2D6-infected (closed bars) CYP2D6 mice at 
week four post-infection after overnight stimulation with the corresponding peptide. 
In summary, we could show that CD4
+ and CD8
+ T cells isolated from wild-
type  FVB/N  mice  infected  with  Ad-2D6,  but  not  Ad-GFP,  produced  IFN-  
after  ex  vivo  stimulation  with  human  CYP2D6  peptides.  These  data 
demonstrate that Ad-2D6-infection results in the breakdown of tolerance to 
human CYP2D6 on both the B cell and T cell level. In addition, we found that 
most CYP2D6-specific T cells were located in the liver of Ad-2D6-infected 
mice  suggesting  targeting  and/or  retention  of  CYP2D6-specific  T  cells.  In 
accordance  with  our  previous  results  indicating  a  partial  tolerance  in 
humanized CYP2D6 mice resulting in a less severe autoimmune liver damage 
we found that T cell tolerance seems to be more stringent in CYP2D6 mice 
then in FVB/N mice.   67
10 Discussion 
10.1 Breaking  tolerance  to  the  natural  human  liver 
autoantigen CYP2D6 by virus infection 
By  infecting  wild-type  FVB/N  and  humanized  CYP2D6  mice  with  an 
adenovirus vector expressing the natural human autoantigen CYP2D6, self-
tolerance to CYP2D6 was broken, resulting in persistent autoimmune liver 
damage. For the first time we could show in an animal model the generation 
of autoantibodies with the same specificity as human LKM-1 occurring in AIH 
type 2 patients, combined with severe and persistent autoimmune-mediated 
hepatic  damage,  characterized  by  massive  hepatocellular  damage,  strong 
cellular infiltration and the development of subcapsular fibrosis. 
10.2 Mouse models for human autoimmune hepatitis 
Several,  mostly  transgenic,  mouse  model  systems  for  AIH  have  been 
introduced in the past. The use of transgenic mice to study autoimmune-
mediated diseases is well established and resulted in numerous theories and 
discoveries  about  the  etiology  and  pathogenic  mechanisms  of  other 
autoimmune diseases. The use of transgenic mice ensures the presence of a 
clearly  defined  antigen  as  a  target  for  the  aggressive  immune  response. 
Further, transgenic mice ensure a tissue-specific expression of the transgene 
that  allows  directing  the  autoimmune-mediated  damage  to  the  tissue  of 
choice  and  it  often  enables  specific  tracking  and  monitoring  of 
autoaggressive  immune  cells  of  interest.  However,  the  expression  of  a 
transgenic  target  antigen  often  leads  to  a  natural  tolerance  of  the  host 
against the transgene since it is considered a self-antigen. In order to break 
this natural tolerance several approaches that lead to specific or unspecific 
activation of autoreactive immune cells can be chosen. First, it is possible to 
overcome  the  natural  tolerance  by  a  massive  unspecific  activation  of  the 
immune  system  by  administration  of  stimulators  of  the  innate  immune 
response.  A  second  possibility  is  to  directly  transfer  activated  antigen-  68
specific lymphocytes in mice expressing the target antigen. A third possibility 
is the enhanced attraction of potential aggressive immune cells by infection 
with a virus that predominantly infects the organ of interest. 
In an animal model of Frank Chisari’s group transgenic mice expressing the 
HBsAg specifically in hepatocytes were generated and tolerance was broken 
by adoptively transferring activated T cells of HBsAg-primed donor mice. It 
was found that transferred HBsAg-specific CTL dominated the autoimmune 
response in HBsAg transgenic mice, released IFN-  upon antigen encounter 
and triggered apoptosis of HBsAg expressing hepatocytes. However, only a 
transient form of hepatic injury was observed which lasted less than three 
weeks following adoptive transfer (71). Nevertheless, this study indicates that 
TH1-mediated  liver damage  can  be  involved  in  autoimmune-mediated  liver 
diseases. 
In  another  model,  the  MHC  class  I  molecule  H-2K
b  was  transgenically 
expressed in the liver of TCR transgenic mice whose T cells carried a H-2K
b-
specific TCR. However, those TCR transgenic T cells were tolerized against 
the  MHC  class  I  molecule  H-2K
b  specifically  expressed  in  the  liver  and 
tolerance could only be broken after additional transfer of cells expressing 
the target antigen H-2K
b and IL-2. Nevertheless, no liver damage could be 
observed  and  additional  infection  with  a  liver-specific  pathogen  was 
necessary to induce transient hepatitis and liver damage reflected in elevated 
ALT indicating that breaking of peripheral tolerance as well as conditioning of 
the liver microenvironment is necessary to cause autoimmune tissue damage 
(72). In a follow up paper from the same group it was shown that injection of 
the  immunostimulatory  CpG-rich  oligodeoxynucleotides  (CpG-ODN)  in  H-
2K
b/TCR  doubletransgenic  mice  was  sufficient  to  initiate  autoimmune-
mediated liver damage caused by H-2K
b-specific CD8
+ T cells. However, in 
order to maintain hepatic damage over a longer period of time  (over eight 
weeks) CpG-ODN had to be repeatedly administrated and termination of this 
inflammatory  stimulus  resulted  in  abrogation  of  disease.  These  findings 
indicated  that  additional  factors  are  required  for  a  self-perpetuation  of 
autoimmunity (83).   69
In another animal model for AIH the immunodominant LCMV-GP expressed 
exclusively in the liver was used as transgene. These mice did not show any 
signs  of  autoimmunity  under  normal  conditions  and  similar  to  the  H-2K
b 
transgenic mice, adoptive transfer of TCR transgenic T cells specific for the 
LCMV-GP expressed in the liver alone was not sufficient to induce disease. 
However, when these mice were infected with LCMV after adoptive transfer 
of  TCR  transgenic  T  cells  specific  for  the  LCMV-GP  a  transient  form  of 
hepatitis developed (73). As with the H-2K
b mice it could be shown with this 
mouse  model  in  a  follow  up  paper  that  strong  activation  of  the  innate 
immune  system  is  enough  to  initiate  transient  autoimmune-mediated  liver 
damage  caused  by  LCMV-GP-specific  CD8
+  T  cells  (84).  As  the  data 
obtained with H-2K
b transgenic mice, these findings indicate that existence 
of autoreactive T cells specific for antigen within the liver is not sufficient to 
initiate autoimmune-mediated liver damage. 
Another mouse model, which uses the well characterized LCMV proteins as 
targets  is  the  TTR-LCMV  mouse  expressing  LCMV-NP  specifically  in  the 
liver. Tolerance to the LCMV-NP was broken by repeated vaccination with 
plasmids  encoding  the  LCMV-NP  and  the  TH1  stimulating  cytokine  IL-12 
genes leading to a NP-specific CTL response, minor cellular infiltrates and 
elevated ALT (74). A related approach was used in another study, in which 
wild-type mice were xenoimmunized with a plasmid containing the human 
antigenic region of CYP2D6 (the target of LKM-1 antibodies) and FTCD (the 
target  of  LC1  antibodies).  However,  minor  elevations  in  serum 
aminotransferase levels, a transient generation of anti-CYP2D6 and anti-LC1 
antibodies and significant inflammation in the liver could only be found after 
co-expression of the TH1 stimulating cytokine IL-12 (75). Nevertheless, both 
of these studies support the data of Moriyama et al that TH1-mediated liver 
damage can play a role in autoimmune-mediated liver damage (71). 
10.3 Lessons learned from animal models for AIH 
Autoimmune diseases are believed to be the result of genetic predisposition 
and environmental triggers such as bystander activation, molecular mimicry   70
or drug metabolism. Therefore, in theory, the liver should be a prime target 
for autoimmunity because it acts as a first line of defense against infectious, 
toxic, or carcinogenic agents arriving from the gut that could all eventually 
trigger activation of autoreactive immune cells either by molecular mimicry, 
bystander  activation  or  neo-antigen  formation.  However,  the  frequency  of 
autoimmune  disease  afflicting  specifically  the  liver  are  relatively  low  when 
compared with other autoimmune diseases. One explanation for this is an 
overall bias of the liver to favor induction of tolerance rather than induction of 
immunity,  which  could  already  be  demonstrated  in  the  late  1960s  by  the 
spontaneous  acceptance  of  liver  allografts  in  many  species  (34).  Several 
mechanism  have  been  proposed  to  be  responsible  for  this  bias  towards 
tolerance  induction  in  the  liver  including  T  cell  inactivation  by  antigenic 
priming  in  the  liver,  tolerance  induction  via  cross-presentation  by  LSEC, 
induction of regulatory T cells by LSEC and hepatic stellate cell-induced T 
cell apoptosis (32, 33, 37, 85, 86). Furthermore, it could be demonstrated 
that  targeted  expression  of  autoantigens  in  liver  cells  can  induce 
autoantigen-specific Treg cells that are able to suppress subsequent induction 
of  an  experimental  autoimmune  disease  in  animals  (41).  This  preferred 
induction of  tolerance  against  antigens  encountered  in  the  liver  made  the 
generation  of  a  reliable  animal  model  to  study  persistent  autoimmune-
mediated liver damage difficult. In most models, liver injury is only transient 
and  can  be  achieved  by  rather  complex  intervention  methods.  Often, 
tolerance to a transgenic antigen expressed exclusively in the liver can only 
be  broken  by  adoptive  transfer  of  either  previously  primed  T  cells  or 
transgenic  T  cells  specific  for  the  target  antigen  in  combination  with 
additional inflammatory triggers such as viral infection or overexpression of 
pro-inflammatory  cytokines.  In  addition  to  the  overall  bias  of  the  liver  to 
induce  tolerance,  the  complex  methods  used  to  trigger  autoimmune  liver 
damage  itself  could  restrict  the  autoimmune  response  leading  to  only 
transient liver damage. For example in models that require the transfer of 
TCR transgenic T cells in mice that transgenically express the target antigen 
it might be possible that the relatively small number of TCR transgenic T cells   71
are confronted with an excess of antigen and therefore, after strong initial 
activation  die  by  apoptosis.  This  process  is  called  exhaustion  or  clonal 
deletion and can be seen for example after i.v. infection of wild-type C57BL/6 
mice with a high dose of 2x10
6 pfu of the fast replicating LCMV Docile (87). 
Another  possibility  how  complex  experimental  methods  may  restrict  the 
resulting  autoimmune  response  in  models  that  require  the  additional 
persistent  expression  of  pro-inflammatory  cytokines  is  that  counteracting 
mechanism in the liver try to balance out the pro-inflammatory milieu in the 
liver.  Nevertheless,  those  animal  models  were  able  to  at  least  transiently 
break  self-tolerance  to  specific  liver  antigens  in  an  autoimmune-mediated 
fashion and could show that TH1-mediated destruction of hepatocytes can 
play a role in autoimmune-mediated liver diseases. In addition, these models 
emphasized that not only breaking of tolerance but also conditioning of the 
liver  microenvironment  plays  an  important  role  for  autoimmune-mediated 
liver damage. 
10.4 The CYP2D6 animal model for AIH 
As found by human studies, the use of animal models for AIH listed above 
and animal models for other autoimmune diseases it is known that genetic 
predisposition  and  breaking  of  tolerance  are  not  sufficient  to  initiate  a 
persistent autoimmune-mediated disease. Current opinion is that activation 
of the innate immune system, inflammatory processes as well as breaking of 
self-tolerance and down-regulation of possible regulatory mechanism might 
have to act in a synergistic fashion in order to initiate autoimmune-mediated 
damage.  One  possibility  to  induce  such  a  complex  scenario  is  molecular 
mimicry  of  host  structures  by  pathogens  and  indeed,  many  autoimmune 
diseases have been associated with pathogen infections (15, 21-24, 47, 88). 
Therefore, our strategy was to build an animal model for AIH based on the 
initial concept of molecular mimicry as a possible cause for autoimmunity. In 
addition, instead of choosing an artificial model antigen to break tolerance 
we used the natural human autoantigen CYP2D6 which constitutes the major 
target autoantigen in human type 2 AIH (57). We used the wild-type FVB/N   72
mice as well as the humanized CYP2D6 mice that transgenically express the 
human CYP2D6 under the control of its own promotor predominantly in the 
liver (77). Natural tolerance to the human CYP2D6 autoantigen was broken 
by  infection  of  mice  with  an  adenovirus-vector  expressing  the  human 
CYP2D6. Using both, the wild-type FVB/N mice that only express the mouse 
CYP2D6  homologues  and  the  humanized  CYP2D6  mice  that  express  the 
transgenic CYP2D6 as well as endogenous CYP2Ds enabled us to have a 
model system for true molecular mimicry (wild-type FVB/N mice) and one for 
molecular identity (humanized CYP2D6 mice). Infecting wild-type FVB/N as 
well  as  humanized  CYP2D6  mice  with  Ad-2D6  resulted  in  an  initial  acute 
hepatitis associated with hepatic adenovirus infection. This was followed by 
a  persistent  autoimmune-mediated  hepatic  damage,  characterized  by 
massive hepatocellular damage, strong subcapsular liver fibrosis as well as 
extensive  subcapsular  and  peri-vascular  infiltration  by  B  cells,  CD4
+  and 
CD8
+ T cells and macrophages. We could demonstrate that B cell tolerance 
was broken after infection with Ad-2D6 resulting in activation of CYP2D6-
specific B cells and the generation of high titers of anti-CYP2D6 antibodies. 
For the first time generation of autoantibodies with the same specificity as 
human  LKM-1  occurring  in  AIH  type  2 patients  could be  generated  in  an 
animal model. In addition, we could show that the disease was less severe in 
humanized CYP2D6 compared to wild-type FVB/N mice, indicating that the 
presence  of  a  self-antigen  in  the  liver  somewhat  protects  against 
autoimmune-mediated immune responses that targets the identical antigen 
present in the liver. Furthermore, we could demonstrate that virus infection 
was essential to induce persistent liver damage. In contrast, virus infection 
was  not  required  for  breaking  of  B  cell  tolerance  and  autoantibody 
production. In addition, T cell tolerance was broken after infection with Ad-
2D6 resulting in the activation of CYP2D6-specific T cells that were able to 
produce IFN-  after ex vivo stimulation. The frequency of IFN-  producing T 
cells  after  overnight  incubation  with  human  CYP2D6  peptides  was 
approximately  ten  times  higher  in  Ad-2D6-infected  wild-type  FVB/N  mice 
compared to transgenic CYP2D6 mice.   73
10.5 Advantages of the CYP2D6 mouse model 
For an animal model to be relevant it needs to resemble the human disease 
and its consequences as much as possible. Autoimmune diseases however, 
are not induced by a single event alone but rather by the accumulation of 
several  factors  including  genetic predisposition  and  environmental  triggers 
that  might  have  occurred  years  before  the  clinical  signs  for  autoimmune 
tissue damage are detectable. Therefore very little is known so far about the 
etiology  of  autoimmune  diseases  and  animal  models  that  after  an  initial 
trigger  lead  to  the  manifestation  of  autoimmune-mediated  tissue  damage 
become  valuable.  Nevertheless,  relevant  animal  models  for  autoimmune 
diseases  should  stay  as  close  to  potential trigger  mechanisms  for  human 
autoimmune diseases as possible and reflect the clinical signs of the disease 
most  accurately.  Often  proposed  environmental  triggers  of  autoimmune 
diseases in humans involve bystander activation, molecular mimicry or neo-
antigen formation by for example drug metabolism (13). The clinical outcome 
of  AIH  that  leads  to  chronic  progressive  liver  damage  and  cirrhosis  is 
characterized  by  the  presence  of  persistent  interface  hepatitis  and  portal 
plasma cell infiltration on histologic examination and autoantibodies (51, 52). 
Some  of  the  animal  models  discussed  above  served  as  experimental 
representation for transient autoimmune-mediated tissue damage. However, 
none of them could reproduce persistent liver damage in the presence of 
autoantibodies  with  the  same  specificity  as  human  LKM-1  antibodies  as 
occurring  in  AIH  type  2  patients.  In  addition,  most  models  used  a  rather 
artificial  and  unphysiological  trigger  mechanism  to  induce  autoimmune-
mediated  tissue  damage  detected  and  only  transient  hepatitis  and 
hepatocellular damage was observed. In contrast, the CYP2D6 mouse model 
based  on  the  initial  concept  of  molecular  mimicry  used  a  trigger  for  the 
induction of autoimmunity that is commonly accepted as one of the possible 
causes  for  human  autoimmune-mediated  diseases.  The  CYP2D6  mouse 
model  resulted  after  an  initial  phase  of  acute  hepatitis  in  persistent 
autoimmune-mediated liver damage. In this context, the CYP2D6 model is 
superior to others as it combines an acute anti-viral hepatitis phase with a   74
chronic  and  progressive  autoimmune-mediated  hepatitis.  Therefore,  the 
CYP2D6 model may offer a unique opportunity to study all mechanisms of 
virus-induced autoimmunity ranging from the initial activation of the innate 
immune system by viral infection to the autoimmune-mediated destruction of 
the liver. 
10.6 The  CYP2D6  mouse  model  and  the  etiology  of 
AIH 
A  common  hypothesis  to  explain  the  etiology  of  autoimmune  disease  is 
genetic  predisposition  of  the  host  paired  with  environmental  triggers  (13). 
Many autoimmune diseases such as T1D, MS, PBC, AIH and others have 
been linked to pathogen infections, however, no firm proof for environmental 
factors, such as viruses, as inducers of most human autoimmune diseases 
has been found as of yet. Nevertheless, for a few rare autoimmune-mediated 
diseases a temporal association between infection and autoimmune diseases 
could  be  proven,  so  for  example  for  rheumatic  fever  in  which  antibodies 
found  after bacterial  infection  cross-react  with  heart  autoantigens  and  are 
postulated  to  lead  to  immune-mediated  anti-heart  autoimmunity  (27)  or  in 
case  of  Guillain-Barré  syndrome  in  which  antibodies  found  after  bacterial 
infection  cross-react  with  peripheral  nerve  gangliosides  (28).  There  are 
several possibilities that can make a direct link of autoimmunity to a single 
infection difficult even thought the fact that infections have the possibility to 
induce strong activation of the innate as well as the adaptive immune system 
and the fact that there are many sequence homologies between pathogenic 
antigens  and  human  autoantigens  suggesting  their  involvement  in  the 
initiation of autoimmunity. First, it is likely that an acute infection that can 
activate autoreactive cells has already been cleared by the time of diagnosis 
of  the  resulting  autoimmune  disease  making  a  causative  association  very 
hard to prove (also referred to as ‘hit and run events’). Second, some virus 
infections are common and traces of these infections can not only be found 
in patients with autoimmune diseases but also in healthy individuals making it 
hard to link those infection to the initiation of the autoimmune disease. Third,   75
viruses  might  not  directly  induce  autoimmunity  but  instead  accelerate  a 
preexisting  autoimmune  condition  to  progress  to  clinical  disease  and  in 
addition,  the  exact  time,  location  and  magnitude of  an  infection  might be 
important. In this context pathogenic infections or strong activators of the 
immune system in general are believed to induce a temporary immunological 
state (also referred to as ‘fertile field’) that can depending on genetic and 
environmental  factors  lead  to  autoimmune-mediated  diseases  (15,  16).  In 
conjunction with the ‘fertile field’ hypothesis we could show in the CYP2D6 
mouse  that  breaking  of  tolerance  alone  was  not  sufficient  to  induce  an 
autoimmune  liver  disease.  Infection  with  a  liver-specific  pathogen  and 
therefore  generation  of  a  fertile  field  in  the  liver  microenvironment  was 
required to cause autoimmune-mediated tissue damage. 
In  human autoimmune  hepatitis,  several  studies  implicate  viruses  such  as 
measles virus, hepatitis virus, cytomegalovirus and Epstein-Barr virus in its 
initiation (53, 89). For example it could be shown that HCV has the potential 
to  induce  autoreactive  CD8
+  T  cells  which  cross-reactively  recognize  the 
cytochrome P450 isoforms 2A6 and 2A7 that contain sequence homology to 
HCV (66). Further, it could be shown that antibodies against CYP2D6 in HCV 
and LKM-1 positive patients can cross-react with the HCV proteins NS3 and 
NS5a  (56).  In  addition,  a  protein  of  HSV-1  has  been  reported  to  share 
sequence homology with the immunodominant CYP2D6 epitope suggesting 
a possibility of molecular mimicry as a mechanism involved in the etiology of 
AIH (57). Using the CYP2D6 mouse model we could demonstrate tolerance 
breakdown  and  triggering  of  persistent  autoimmune-mediated  hepatic 
damage not only in humanized CYP2D6 mice that confer molecular identity 
with the Ad-2D6 virus, but also in wild-type FVB/N mice that only express the 
mouse CYP2D isoenzymes. Mouse CYP2Ds confer high sequence homology 
to the human CYP2D6 and several mouse CYP2Ds, including the CYP2D22 
that has been suggested to be the functional ortholog of human CYP2D6 (79) 
display up to 75% aa sequence homology to the human CYP2D6. Therefore, 
breaking of tolerance and persistent autoimmune-mediated liver damage in 
wild-type  FVB/N  mice  was most  likely  induced  because of  true molecular   76
mimicry between the human CYP2D6 expressed by the adenovirus system 
and homologous mouse CYP2D sequences. 
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Figure 23: Possible mechanism for induction of AIH 
Infection with a liver-tropic pathogen leads to the production of pro-inflammatory cytokines 
and  chemokines  that  will  then  attract  APCs  and  lymphocytes  of  all  sorts.  Lymphocytes 
specific  for  pathogen  antigens  (several  possibilities)  will  expand  and  start  to  destroy  the 
pathogen-infected hepatocytes leading to an acute hepatitis. The accumulation of specific 
as  well  as  unspecific  lymphocytes  in  combination  with  APCs  and  soluble 
chemokines/cytokines  due to  pathogen infection is  also referred to as  fertile  field. Under 
normal circumstances the pathogen and pathogen-infected cells will be eliminated and the 
liver regenerates itself. However, especially in genetically predisposed individuals there is the 
possibility that autoreactive lymphocytes are being activated by either bystander activation 
or  by  pathogen  antigens  mimicking  self-antigens.  Those  autoreactive  lymphocytes  will 
expand and target self-cells and start to destroy the liver parenchyma. Clinical signs of an 
autoimmune disease might only be detectable after several months. 
Interestingly,  we  found  that  the  disease  was  less  severe  in  humanized 
CYP2D6  compared  to  wild-type  FVB/N  mice.  These  findings  allow  the 
speculation that similar yet not identical autoantigens might be better targets   77
for autoimmune reactions afflicting the liver due to less efficient central and 
peripheral tolerance mechanism. 
Taken  together  we  could  demonstrate  by  the  use  of  the  CYP2D6  mouse 
model  that  persistent  immune-mediated  hepatitis  can  be  triggered  by 
molecular mimicry occurring in the context of a hepatotropic viral infection. 
These results support the evidence that molecular mimicry in combination 
with environmental factors such as viruses that can induce a ‘fertile field’ for 
the  arrival  of  autoaggressive  lymphocytes  in  the  liver  microenvironment  is 
one of the possible mechanisms involved in the etiology of AIH (see Figure 
23). 
10.7 The  CYP2D6  model  and  pathogenic  mechanism 
of AIH 
The  outcome  of  AIH  is  autoimmune-mediated  persistent  liver  infiltration 
leading  to  progressive  hepatocellular  damage  and  the  development  of 
fibrosis.  However,  as  of  yet  not  much  is  known  about  the  underlying 
pathogenic  mechanisms  that  lead  to  destruction  of  hepatocytes  in  an 
autoimmune-mediated fashion. The presence of increased numbers of B and 
T lymphocytes, plasma cells and macrophages within the liver parenchyma 
(interface hepatitis) during an ongoing AIH in human patients as well as the 
presence of disease-specific autoantibodies indicates that several pathways 
may be contributing to the clinical manifestation of the disease. 
Although there is relatively much known about the autoantibodies especially 
in AIH type 2 it is still not clear if they indeed play a role in the pathogenic 
mechanisms  of  AIH.  It  could  be  shown  that  LKM-1  autoantibodies,  the 
hallmark of type 2 AIH, do recognize and bind to CYP2D6 exposed on the 
plasma membrane of hepatocytes (60) and that anti-LC1 antibodies, specific 
for AIH type 2 but only present in up to 50% of patients, seem to correlate 
with disease activity (61). In addition, residual plasma cells in the liver tissue 
of  patients  before  withdrawal  of  immunosuppressive  therapy  are  more 
frequently  associated  with  relapse  than  with  sustained  remission  (90).   78
However, the pathogenic role of autoantibodies in AIH is not yet resolved (91)  
and since autoantibodies related to AIH also appear in other chronic liver 
disease  (LKM-1 antibodies in chronic HCV patients) and even in up to 15% 
of healthy individuals (in case of the ANA antibodies found predominantly in 
AIH type 1) it is unlikely that autoantibodies alone are responsible for the 
autoimmune-mediated tissue damage seen in AIH (53, 54). Supporting the 
theory  that  autoantibodies  alone  are  not  sufficient to  induce  autoimmune-
mediated liver damage in human AIH, we found in our CYP2D6 animal model 
that  treatment  of  mice  with  human  recombinant  CYP2D6  alone  or  in 
combination with Poly-IC, CpG, IFA or CFA resulted in breakdown of B cell 
tolerance but not autoimmune liver disease. Besides the strong association 
of MHC haplotypes with genetic susceptibility and a more severe form of 
AIH,  several  studies  have proposed the  involvement of  T cell  immunity  in 
human AIH as well as in animal models for AIH (53). As described previously 
several animal models for AIH could show the involvement of TH1-mediated 
hepatocellular  destruction  by  CD8
+  T  cells  in  autoimmune-mediated  liver 
damage  (71,  74,  75).  However,  in  those  models  either  a  TH1  promoting 
cytokine or already activated CTL were used to shift the immune response 
towards an aggressive CD8
+ T cell response. Nevertheless, also in human 
AIH recent studies have identified CYP2D6-specific CD8
+ T cells capable of 
secreting  IFN-   and  of  exerting  cytotoxicity  after  recognition  of  CYP2D6 
epitopic sequences in an HLA class I restricted fashion (92). In correlation 
with the data received for human AIH type 2 patients we could show in the 
CYP2D6 model that CD8
+ T cells isolated during an ongoing autoimmune-
mediated liver disease produce IFN-  after ex vivo stimulation with specific 
peptide-epitopes of CYP2D6 further supporting the theory that MHC class I 
restricted killing of hepatocytes is involved in AIH. 
CD4
+  T  cells  can  influence  immunity  in  several  ways  depending  on  the 
cytokine  profile  secreted.  They  can  either  skew  the  immune  response 
towards a more aggressive TH1 response involving CD8
+ T cells or towards 
the  less  aggressive  TH2  response  leading  to  the  activation  of  B  cells  and 
production  of  antibodies.  Already  in  the  1980’s  it  could  be  shown  that   79
patients with AIH have lower levels of circulating T cells expressing CD8 co-
receptors  (93)    indicating  a  regulation  towards  the  less  aggressive  TH2 
response. Relatively newly described CD4
+ T cell subsets, Treg cells and TH-
17 cells have been implemented to play an important role in autoimmune 
diseases.  Treg  cells  are  described  as  a  weakly  self-reactive  CD4
+  T  cells 
subset  that  is  able  to  suppress  either  specifically  or  via  bystander 
mechanisms  autoreactive  immune  cells  (5,  8)  whereas  the  highly  pro-
inflammatory CD4
+ TH-17 cells are believed to play an important role during 
the initiation and propagation of an autoimmune disorder (4). So far nothing 
is known about TH-17 and their role in AIH, whereas it could be shown that in 
patients with AIH Tregs are defective both in number and function compared to 
normal  controls  and  that  these  abnormalities  related  to  the  stage  of  the 
disease (4, 92, 94, 95). In a more classical approach, it could be shown that 
CD4
+  T  cells  from  AIH  type  2  patients  did  proliferate  and  were  able  to 
produce  IFN- ,  IL-4  and  IL-10  after  ex  vivo  stimulation  with  overlapping 
peptides  covering  the  whole  CYP2D6  gene  (63).  In  addition,  they  could 
correlate  the  number  of  epitopes  recognized  and  the  quantity  of  IFN-   (a 
typical  TH1  cytokine)  and  IL-4  (a  typical  TH2  cytokine)  produced  with 
biochemical  and  histological  markers  of  disease  activity  suggesting  a 
pathogenic role of both TH1 and TH2 T cells in AIH type 2 (63). By the use of 
the exact same overlapping peptides spanning the whole CYP2D6 gene used 
in the study of Ma et al. we were able to show in the CYP2D6 model that 
CD4
+ T cells isolated during an ongoing autoimmune-mediated liver disease 
were able to produce IFN-  after ex vivo stimulation. Since IFN-  is known to 
be a typical TH1 cytokine but also promotes antibody class switching to the 
mostly anti-viral isotype IgG2a (96) it is possible that TH1- as well as TH2-
mediated pathogenic mechanism are involved in the detected autoimmune 
liver disease in the CYP2D6 mouse model. Interestingly, IgG2a binds with 
high affinity to Fc RI expressed on macrophages, neutrophils, mast cells and 
natural killer cells (97, 98). In this context it is imaginable that opsonization of 
anti-CYP2D6 coated hepatocytes by Kupffer cells could play a pathogenic 
role in our model as well.   80
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Figure 24: Possible pathogenic mechanism in the CYP2D6 model 
Adenovirus  infection  leads  to  an  initial  acute  hepatitis  in  combination  with  hepatocellular 
damage. Virus antigens as well as self-antigens can then be taken up by residual or invaded 
APCs, processed and presented to CD4
+ T helper cells or directly to CD8
+ T cell. The CD4
+ T 
helper cell becomes activated and according to the cytokine profile present and the nature 
of the antigen differentiates either in a TH1 type or TH2 type CD4
+ T helper cell. TH1 type CD4
+ 
T cells will activate CD8
+ T cells that then differentiate into IFN-  producing CTLs whereas 
TH2  type  CD4
+  T  cells  will  activate  B  cells  that  then  differentiate  into  plasma  cells  and 
produce  antibodies.  One  or  both  effector  cells  (CTL  and  plasmacells)  respectively  their 
products (IFN-  or antibodies) can target hepatocytes and cause the autoimmune-mediated 
hepatocellular damage seen during the persistent autoimmune phase in the CYP2D6 model. 
Besides the classical differentiation of CD4
+ T helper cells to TH1 type or TH2 type CD4
+ T 
helper cells it is possible that TH-17 and/or Treg  cells are generated that can  augment or 
abrogate the autoimmune process. However, the involvement of TH-17 and/or Treg cells in 
initiation  and  propagation  or  regulation  of  the  autoimmune  response  still  needs  to  be 
evaluated.  HSC  will  get  activated  and  produce  collagen  fibers  leading  to  fibrosis.  Thin 
arrows  indicate  assumptions  that  have  not  been  tested  by  experiments  yet  while  thick 
arrows indicate processes that have been confirmed by experimental testing in the CYP2D6 
mouse model. 
Comparing wild-type FVB/N and humanized CYP2D6 mice we found a less 
severe  autoimmune  liver  damage  in  humanized  CYP2D6  mice.  Our  data   81
showed only a minor decrease in the autoimmune B cell response measured 
by  autoantibody  production.  In  contrast,  the  autoimmune  T  cell  response 
measured by IFN-  production after ex vivo CYP2D6 peptide stimulation was 
strongly decreased. Those findings confirm the theory that B cell tolerance is 
less  stringent  controlled  then  T  cell  tolerance  (99,  100)  and  support  the 
involvement of TH1- as well as TH2-mediated pathogenic mechanism in our 
mouse model for autoimmune mediated liver damage (summarized in Figure 
24). 
10.8 Possibilities of the CYP2D6 mouse model 
In summary we conclude that the CYP2D6 mouse model has the following 
advantages over other animal model systems described for AIH: 
•  It has a well-defined and feasible initiating event that constitutes one 
of  the  possible  mechanisms  leading  to  the  initiation  of  human  AIH 
(molecular mimicry). 
•  It uses the natural occurring autoantigen, the human CYP2D6 under 
its own promotor as a target antigen for the autoimmune response. 
•  It resembles the autoimmune response of human AIH type 2 by the 
production of LKM-1-like autoantibodies and the activation of T cells 
specific for CYP2D6 autoantigens 
•  It reflects the outcome of human AIH type 2 in persistent autoimmune-
mediated  hepatic  damage,  characterized  by  massive  hepatocellular 
damage,  strong  cellular  infiltration  and  the  development  of 
subcapsular fibrosis. 
Being  that  close  to  the  human  autoimmune  disease  the  CYP2D6  mouse 
model  holds  potential  for  the  dissection  of  the  mechanisms  underlying 
human  AIH.  Following  approaches  might  help  to  understand  the  complex 
processes involved: 
•  It will be necessary to further study the cellular immunity, involving the 
analysis of classical T cell subsets contributing to the autoimmune-
mediated liver damage.   82
•  Newly defined T cell subsets such as Treg, TH-17 and TH-9 cells and 
their contributions in abrogation/prevention or initiation of the disease 
have to be investigated. 
•  Adoptive transfer experiments, in which sorted cell populations and/or 
serum from diseased animals are transferred to healthy animals can 
be used to clarify whether cellular subsets or serum factors can induce 
or suppress an autoimmune-mediated liver disease. 
•  The CYP2D6 model crossed to several other transgenic or knockout 
mice  could  enable  a  better  understanding  of  the  potential 
contributions  of  humoral  and  cellular  immunity  to  hepatic 
autoimmunity. 
The  CYP2D6  mouse  model  can  not  only  be  used  to  understand  the 
mechanisms  underlying  human  AIH  but  also  serve  as basis  to  investigate 
possible  intervention  strategies  for  autoimmune  liver  diseases.  Possible 
therapies  include  administration  of  cytokines  or  neutralizing  antibodies 
against them. It could be demonstrated in animal models for T1D that the 
effect of cytokines depends on the timing of administration, the dose and the 
route of administration (101-104). Further, depletion of lymphocyte subsets, 
such as CD3
+ T cells, as currently in use for T1D (105) could have positive 
effects  on  an  ongoing  autoimmune-mediated  liver  disease  by  deleting 
autoreactive  T  cells.  Finally,  oral/nasal  administration  of  CYP2D6  could 
induce liver antigen-specific Treg cells as it could be shown in other animal 
models  for  autoimmune  diseases  (106,  107).  However,  most  of  these 
approaches depend on the right timing during the course of an autoimmune 
disease and a successful intervention might be bound to a certain time point 
during  the  development  of  the  disease  (also  referred  to  as  ‘window  of 
opportunity’).  Furthermore,  a  combination  therapy  might  be  the  most 
successful  approach  as  recently  demonstrated  in  T1D  (108,  109).  In  a 
combination  therapy,  the  depletion  of  CD3
+  T  cells  is  combined  with  the 
induction of Treg cells by administration of intra nasal autoantigen during the 
re-establishment of the immune homeostasis.   83
The use of an animal model that has a well-defined initiation of the disease 
such as the CYP2D6 model will allow the investigation of such intervention 
methods and the effects they have on the outcome of autoimmune-mediated 
liver damage.   84
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Figure 25: 61 20mer sequences spanning the entire human CYP2D6 
Schematic  overview  of  the  61  overlapping  20mer  sequences  spanning  the  entire  human 
CYP2D6 gene received through collaboration  with D. Bogdanos and D.  Vergani  from the 
King’s College London School of Medicine at King’s College Hospital   85
12 Material and Methods 
12.1 Source of Materials 
12.1.1  Plastic ware 
70 µm nylon cell strainer  BD Falcon; 352350 
96-well ELISA plates  Anicrin; 3911925 
96-well V-bottom plates  Anicrin; 3911924 
Cell culture flasks (25, 75, 175 cm
2)  Cellstar 
Coverslip  Menzel-gläser 
Cryomolds  Electron Microscopy science; 62352-30 
Cryotubes  Sarstedt; 72.379.002 
Eppendorf tubes  Eppendorf 
FACS-tubes  Biorad; 223-9390 
FACS-tubes  BD Falcon; 352052 
Falcon tubes (15, 50 ml)  Cellstar 
Heparin coated capillary  Fisher scientific; 02-668-10 
Needles (27G, 30 G)  BD Microlance 
Plastic pipets (5, 10, 25, 50 ml)  Corning INC 
Sialin coated slides  Menzel-gläser; J1800AMN/ 
Sterile Filter (500 ml)  Millipore; SCGPU05RE 
Syringes (1 ml)  Terumo; BS-01T 
Syringes (5, 10 ml)  Braun 
Tissue culture dishes  Cellstar 
Tissue culture plates (6, 12, 24, 48, 96 well)  Cellstar 
12.1.2  Chemicals 
Abnormal Control Assay Standard  Biotron Diagnositcs INC.; 01BTAbn 
Acetic Acid  J.T. Baker; 6052 
AEC (3-Amino-9-Ethylcarbazole)  MP Empowered Discovery; 195039 
Agarose  Sigma; A9539 
APS  Sigma; A3678 
Aquamount  Merck; 1.08562.0050 
Avidin Solution  Vector; T1115 
Biotin Solution  Vector; T0821 
Brefeldin A  Sigma; B6542   86
Bromophenol blue  Roth; 512.1 
CFSE  (5-  (and  6-)  carboxyfluorescein 
succinimidyl ester 
Invitrogen; C1157 
Chloroform  Riedel-de Haën; 32211 
Complete freunds adjuvant  Sigma; F5881 
Crystal violet  Sigma; C0775 
DEPC (Diethylpyrocarbonate)  Sigma; D5758 
DMSO (Dimethylsulfoxide)  Sigma; D5879 
DTT (1,4-Dithiothreit)  Roth; 6908.1 
ECF substrate  Amersham Bioscience; RPN 5785 
EDTA  AppliChem; A1103.1000 
Ethanol absolut  Riedel-de Haën; 24102 
Ethidium bromide  Sigma; E8751 
EZ-link sulfo-NHS-LC biotin  Pierce; 21336 
Formaldehyde  Redel-de Haën; 33220 
Glycerol  Roth; 3783.1 
H2O2  Roth; 8070.1 
HCl  Riedel-de Haën; 30721 
Hematoxylin  AppliChem A4840.1000 
HEPES  Gibco; 15630 
Immunofluore mounting Medium  ICN; 622701 
Incomplete freunds adjuvant  Sigma; F5506 
Ionomycin  Sigma; I0634 
Isofluran  Abbott; B506 
Iso-Propanol  Prolabo; R11-36-67 
Methanol  Fluka; 65543 
Na2CO3  Sigma; S7795 
NaCl  J.T. Baker; 0278 
NaHCO3  Merck; 1.06329.0500 
Na-N3  Roth; K305.1 
NH4Cl  Merck; 1.01145.0500 
Normal Control Assay Standard  Biotron Diagnostics INC.; 68665 
Paraformaldehyde  Merck; 1.04005.1000 
Pen/Strep  Gibco; 15140 
Percoll  GE Healthcare; 17-0891-01 
Peroxidase substrate  Vector; SK-4100 
PMA (4 -Phorbol-12-myristate 13-acetate)  Sigma; P148 
Potassium acetate 
 
Merck; 1.04820.1000   87
Rotiphorese  Gel  30  (30%  Acrylamide/0.8% 
bis-acrylamide) 
Roth; 3029.1 
Saponin  Sigma; S7900 
SDS  Roth; 2326.2 
Skim milk powder  Töpfer Allgäu; 60226 
Sodium Pyruvate  Gibco; 11360 
Syrius red solution (120 µl Sirius red in 0.1% 
saturated picric acid) 
Electron Microscopy Sciences; 26357-02 
TEMED  Roth; 2367.3 
Tissue-Tek OCT  Sakura; 4583 
Tri-Reagent  Sigma; T9424 
Tris-HCl  Roth; 4855.2 
Triton X-100  Sigma; T8787 
Trypan blue  Sigma; T8154 
Tween-20  Sigma; P7949 
Xylene  Riedel-de Haën; 16446 
12.1.3  Composition  of  buffers,  solutions  and  culture 
media 
0.1% Crystal violet  0.1% crystal violet 
0.2% EtOH in ddH2O 
0.5% Trypsin-EDTA  Gibco; 25300 
2x Laemmli sample buffer  20% v/v Upper gel buffer 
20% v/v Glycerol 
4% SDS 
1.54% DTT 
bromophenol blue 
35% Percol buffer  35 ml Percol 
4 ml 10x PBS and 60 ml PBS 
ABC reagent solution (Peroxidase Substrate 
Kit DAB) 
5 ml ddH2O 
4 drops of DAB Stock solution 
2 drops of Hydrogen Peroxide Solution 
AEC-substrate  AEC  diluted  1:50  with  50  mM  Na-acetate 
buffer (pH 5) 
filtered through 0.2 µm filter 
30% H2O2 1:2000 
Biotinylation buffer  PBS 
1 mM MgCl2 
0.1 mM CaCl2 
pH 7.4 
1 mg/ml freshly added biotin   88
Collagenase buffer  0.2 mg/ml collagenase IV 
0.02 mg/ml DNase 
5% FCS 
DEPC H2O  1% DEPC in ddH2O 
stir over night and autoclave 
DMEM + GlutaMax I  Gibco; 61965 
ELISA blocking buffer  PBS 
2% FCS 
ELISA coating buffer  50 mM Na2CO3 
50 mM NaHCO3 
pH 9.6 
ELISA/ELISPOT washing buffer  PBS 
0.05% Tween-20 
FACS fixation buffer  PBS 
0.1% PFA 
FACS PBS/saponin buffer  PBS 
1% FCS 
0.1% NaN3 
0.1% Saponin 
FACS PBS/staining buffer  PBS 
1% FCS 
0.1% NaN3 
FACS PFA/saponin buffer  PBS 
0.1% Saponin 
10 mM HEPES 
4% PFA 
FCS (Foetal calf serum)  Biochrom AG; S0115 
IMDM  Gibco; 21980 
Lower gel buffer  1.5 M Tris-HCl (pH 8.8) 
Autoclave 
Medium 199 (10x)  Gibco; 21180-021 
PBS  Gibco; 14190 
Proteinase K  10 mg/ml Proteinase K 
10 mM Tris-HCl (pH 7.5) 
Proteinase K buffer  ddH2O 
20% SDS 
5 M NaCl 
1 M Tris (pH 8) 
0.5 M EDTA 
Red blood cell lysis buffer  0.83% NH4Cl in ddH2O 
Sterile filtrated 
RPMI 1640 + GlutaMax I  Gibco; 61870   89
Running buffer  25 mM Tris 
192 mM Glycine 
0.1% SDS 
pH 8.3 
SPOT washing buffer  PBS 
0.1% Tween-20 
TAE buffer  40 mM Tris-Acetate 
1 mM EDTA 
Transfer buffer  1.44% Glycine 
0.3% Tris 
80% v/v ddH2O 
20% v/v MeOH 
Upper gel buffer  0.5 M Tris-HCl (pH 6.8) 
Autoclave 
12.1.4  Enzymes and proteins 
Collagenase IV  Sigma; C5138 
DNase  Sigma; DN25 
Human recombinant Cytocrome P450 2D6  Invitrogen; P2774 
Human recombinant IL-2  Cell Concepts; C-20002-F 
M-MLV-reverse transcriptase  Promega; M1705 
Proteinase K  Carl Roth; 7528.1 
RNase OUT  Invitrogen; 10777-019 
RQ1 RNase-free DNase  Promega; M6101 
Superscript II reverse transcriptase  Invitrogen; 18064-022 
Taq-polimerase  Peqlab Biotechnologie GmbH; 01-1030 
12.1.5  Nucleotides and nucleic acids 
61x  20mer  sequences  of  cytocrome  P450 
2D6 
Ma et al. Gastroenterology 2006 (Figure 25) 
CpG  IDT; ODN1826 
CYP2D6 F Primer  5’ AGA AGG GGA AGC AGG TTT G 3’ 
CYP2D6 R Primer  5’ CGG CAC TCA GGA CTA ACT CAT C 3’ 
dNTP  Peqlab; 20-2011 
Random Primers  Fermentas; S0142   90
12.1.6  Antibodies 
Antibodies used for FACS-staining 
APC-anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  Southern Biotech; 1550-11 
FITC-anti-mouse CD4/L3T4 (Clone GK 1.5)  Southern Biotech; 1540-02 
FITC-anti-mouse CD45R/B220 (RA3-6B2)  BD Pharmingen; 553088 
FITC-anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  Southern Biotech; 1550-02 
PE-anti-mouse CD11c (p150/90)  eBiosience; 12-0114-82 
PE-anti-mouse IFN-   BD Pharmingen; 5544412 
PE-Cy5-anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  Southern Biotech; 1550-16 
Streptavidin-APC  Southern Biotech; 7100-11M 
Antibodies used for ELISA 
AP-goat anti-mouse IgG  Southern Biotech; 1030-04 
AP-goat anti-mouse IgM  Southern Biotech; 1020-04 
AP-rat anti-mouse IgE  Southern Biotech; 1130-04 
Antibodies used for ELISPOT 
Biotinylated-goat anti-mouse IgG ( -chain-specific)  Southern Biotech; 1030-08 
Biotinylated-goat anti-mouse IgM (µ chain-specific)  Southern Biotech; 1020-08 
Goat anti-mouse IgG+IgA+IgM (H+L)  Caltag Laboratories; M30900 
HRPO-Avidin D  Vector Laboratories Inc.; A-2004 
Antibodies used for Western Blot 
IRDye800-Donkey anti-mouse IgG (H+L)  Rockland; 610-732-124 
IRDye800-Donkey anti-rabbit IgG (H+L)  Rockland; 611-732-127 
Rabbit anti-Adenovirus type 5  Abcam; ab6982 
Rabbit anti-Cytocrome P450 2D6  Abcam; ab4238-50 
Antibodies used for Histology 
Anti-mouse CD4/L3T4 (Clone GK 1.5)  BD Pharmingen; 553043 
Anti-mouse CD45R/B220 (RA3-6B2)  BD Pharmingen; 553084 
Anti-mouse CD8a/Lyt-2 (Clone 53-6.7)  BD Pharmingen; 553027 
Anti-mouse Collagen type I  Chemicon; AB765P 
Anti-mouse F4/80  Serotec; MCAP497 
Biotinylated anti-goat IgG (H+L)  Vector; BA-5000 
Biotinylated anti-Guinea Pig IgG (H+L)  Vector; BA-7000 
Biotinylated anti-hamster IgG (H+L)  Vector; BA-9100 
Biotinylated anti-rabbit IgG (H+L)  Vector; BA-1000 
Biotinylated anti-rat IgG (H+L)  Vector; BA-4001 
Antibodies used for B cell epitope mapping 
IRDye800-Donkey anti-mouse IgG (H+L)  Rockland; 610-732-124   91
12.1.7  Kits 
Alanine aminotransferase assay  Biotron Diagnostics INC.; 68-D 
Asparate aminotransferase assay  Biotron Diagnostics INC.; 66-D 
Avidin/Biotin blocking Kit  Vector; SP-2001 
Cytotoxicity Detection Kit (LDH)  Roche; 11644793001 
Mouse B cell enrichment Kit  EasySep; 19754 
Mouse T cell enrichment Kit  EasySep; 19751 
Peroxidase Substrate Kit DAB  Vector; SK-4100 
Quantitec SYBR Green PCR  Qiagen; 204143 
RNeasy Mini Kit  Quiagen; 74104 
Roti-Histokitt  Roth; 6638.1 
Roti-Quant Protein assay  Roth; 
SlowFade Antifade Kit  Molecular Probs; S2828 
12.1.8  Human Sera 
All  human  sera,  kindly provided by  Prof.  Dr.  M.  P. Manns,  were  from  the 
human serum library of the Department of Gastroenterology, Hepatology and 
Endocrinology  of  the  Medizinische  Hochschule  Hannover  and  have  been 
previously  tested  for  antigen-specificity  by  standardized 
immunofluorescence  and  competitive  ELISA  procedures.  All  patients  have 
been  clinically  diagnosed  with  either  type  of  AIH  or  PBC.  The  blood 
procurement protocol and analysis was approved by the Ethics Committee 
of the Medizinische Hochschule Hannover. 
12.1.9  Cell lines 
HEK-293 are adherent epithelial cells from human fetal kidney that contain 
left end sequences of the adenovirus 5 DNA (RF32764) and were originally 
provided by F.L. Graham. ATCC Nr: CRL-1573. 
12.1.10  Viruses 
Ad-2D6, obtained via Prof. Eric F. Johnson (The Scripps Research Institute, 
La Jolla, CA) was created by homologous recombination in Escherichia coli 
BJ5183  between  a  shuttle  vector  containing  the  cDNAs  for  CYP2D6  and 
pAdE1
-E3
- (82).   92
Ad-GFP was a gift from D.J. von Seggern (The Scripps Research Institute, La 
Jolla, CA). 
12.1.11  Mice strains 
CYP2D6 humanized mice, generated by microinjection of the entire human 
CYP2D6 gene, including its promoter region, into the pronucleus of fertilized 
FVB/N mouse eggs to produce a transgenic mouse line (77), were provided 
by F.J. Gonzalez (National Cancer Institute, Bethesda, MD). 
Wild-type  FVB/NHsd  mice  were  purchased  from  the  breeding  colony  of 
Harlan Netherlands. 
Wild-type C57BL/6 mice were purchased from the breeding colony of Harlan 
Netherlands. 
Wild-type Balb/c mice were purchased from the breeding colony of Harlan 
Netherlands. 
Experiments were carried out with age- and sex-matched animals kept under 
specific  pathogen  free  (SPF)  conditions  and  in  accordance  with  German 
regulations. All animal experiments were approved by the local Ethics Animal 
Review Board (Darmstadt, Germany). 
12.2 Methods 
12.2.1  Cell biological methods 
12.2.1.1  Cultivation of cells 
Cells were cultured in plastic cell culture flasks (25, 75 or 175 cm
2) at 37°C 
(5% CO2, relative humidity 95%) with appropriate medium. 
Adherent  cells  were  split  when  confluent.  For  this,  medium  was  removed 
from the culture flask, the cellular monolayer was rinsed with 10 ml sterile 
PBS and the cells were incubated for 5–10 minutes at 37°C in 3 ml of trypsin-
EDTA solution to detach the cells from the plastic. The detached cells were 
collected, resuspended in appropriate medium and split.   93
12.2.1.2  Freezing of cells 
A  freezing  container  was  pre-cooled  for  30  minutes  at  4°C.  The  freezing 
medium  was  prepared  containing  90%  FCS  and  10%  DMSO.  Cells  were 
trypsinized, washed with PBS and centrifuged at 1,500 rpm for five minutes. 
Cells were re-suspended in 1 ml of pre-cooled freezing medium and 1 ml 
aliquots were transferred into cryotubes. The aliquots were placed into the 
freezing container and transferred to -70°C. The freezing containers ensure 
that the cell samples are cooled down to –70°C at a rate of 1°C/min. After 48 
hours, the cryotubes were transferred to the liquid nitrogen tank (–196°C). 
12.2.1.3  Thawing of cells 
Cell  aliquots  were  taken  out  of  the  liquid  nitrogen  tank  and  warmed 
immediately in a water bath to 37°C. Cells were transferred to a 50 ml Falcon 
tube and the appropriate medium was added slowly in the beginning until 
20x the freezing volume was achieved. This procedure prevents cell damage 
due  to  osmotic  shock.  Cells  were  centrifuged and  washed again  with the 
medium. They were checked for their viability by trypan blue stain. Cells were 
cultured  in  appropriate  conditions  and  the  following  day  the  cells  were 
evaluated for viability and density. 
12.2.1.4  Determining the density of a cell suspension 
The cellular density of a suspension was determined by mixing 10-20 µl of 
the cell suspension with an equal volume of Trypan blue solution. The cells in 
the resulting suspension were counted directly in a Neubauer chamber using 
a microscope. Dead cells were identified by cytoplasmic staining with Trypan 
blue. A grid at the bottom of the chamber was used to count the cells and 
the cell density (cells per ml) was calculated with the following formula: 
Cellular density (cells/ml) = number of cellson the grid   dilution factor 10
4 ml
 1 
12.2.1.5  Isolation of liver lymphocytes 
Liver cells were isolated by squeezing the liver through a 70 µm nylon cell 
strainer  with  a  syringe  plunger  in  10  ml  PBS.  The  cell  suspension  was   94
transferred to a 50 ml falcon tube and 10 ml collagenase buffer was added. 
After 45 – 60 minutes incubation at 37°C the cell suspension was centrifuged 
at 30 g for three minutes and the supernatant was transferred to a fresh 50 
ml falcon tube. The supernatant was centrifuged at 650 g for 10 minutes and 
the pellet was resuspended in 20 ml percoll buffer and centrifuged again at 
600 g for 20 minutes. The liver lymphocytes in the pellet were resuspended in 
RPMI 10% FCS and kept at 4°C until use. 
12.2.1.6  Isolation of splenocytes 
Spleen cells were isolated by squeezing the spleen through a 70 µm nylon 
cell strainer with a syringe plunger in 10 ml RPMI. With a pipette a single cell 
suspension was prepared in 10 ml RPMI. Residual tissue was removed by a 
quick spin at 1200 rpm for 10 seconds. The supernatant was centrifuged at 
1500 rpm for five minutes at 4°C. To eliminate the red blood cells the pellet 
was resuspended in 5 ml 0.83% NH4Cl in PBS and incubated for one to two 
minutes at room temperature. To stop the reaction 5 ml RPMI 10% FCS was 
added and the cells were centrifuged at 1500 rpm for five minutes at 4°C. 
The cell pellet was resuspended in RPMI 10% FCS and the cells were kept at 
4°C until use. 
12.2.1.7  Enzyme Linked Immunosorbent Assay (ELISA) 
To  detect  antibodies  specific  for  human  CYP2D6,  96-well  microtiterplates 
were coated overnight at 4°C with 0.25 µg/ml recombinant human CYP2D6 
in 100 µl of ELISA coating buffer and plates were blocked with 200 µl ELISA 
blocking  buffer  for  90  minutes  at  room  temperature.  Blocking  buffer  was 
removed and the plates were washed four times with 150 µl ELISA washing 
buffer. Sera were added in PBS containing 2% FCS and were incubated for 
90  minutes  at  37°C.  The  dilution  series  for  each  serum  started  at  1:300, 
followed  by  1:3  dilution  steps  down  to  a  final  dilution  of  1:656,100.  After 
washing  the  plates  four  times  with  ELISA  washing  buffer  100  µl  alkaline 
phosphatase labeled goat anti-mouse IgM or IgG antibody diluted 1:2000 in 
PBS  containing  2%  FCS  was  added  for  90  minutes.  After  washing  an   95
additional four times with ELISA washing buffer the reaction was developed 
by addition of 30 µl ECF substrate. Fluorescence intensity was determined 
using a Storm 560 (GE Healthcare Bio-Sciences). Sera dilutions with values 
of three standard deviations above the mean value of negative controls were 
considered positive. 
12.2.1.8   Detection of antibody-secreting cells (ELISPOT) 
To  detect  total  or  CYP2D6-specific  antibody-secreting  cells,  96-well  filter 
plates were coated with 5 µg/ml of goat anti-mouse IgG+IgA+IgM or 0.25 
µg/ml  human  CYP2D6  in  PBS  overnight  at  4°C.  After  washing  the  plates 
once with 200 µl ELISPOT washing buffer and three times with 200 µl PBS 
the plates were blocked with 10% FCS in RPMI 1640 for two hours at room 
temperature. Total splenocytes diluted in DMEM containing 10% FCS were 
added in triplicates and incubated for five hours at 37°C in 5% CO2. The 
dilution  series  for  each  sample  started  at  1x10
6  cells  in  the  first  row  and 
5x10
5 cells in the 2
nd row, followed by six 1:3 dilution steps. After washing the 
plates three times with 200 µl PBS and three times with ELISPOT washing 
buffer  50  µl  biotinylated  goat  anti-mouse  IgG  diluted  1:1000  in  PBS 
containing  0.05%  Tween-20  and  1%  FCS  was  added  and  plates  were 
incubated  overnight  at  4°C.  Plates  were  washed  four  times  with  200  µl 
ELISPOT  washing  buffer.  50  µl  1:1000  diluted  horseradish  peroxidase-
conjugated Avidin D in PBS containing 0.05% Tween-20 and 1% FCS was 
added for 60 minutes at room temperature. After washing the plates three 
times  with  200  µl  ELISA  washing  buffer  and  three  times  with  PBS  the 
reaction was developed by the addition of freshly prepared AEC substrate. 
12.2.1.9  Flow cytometry 
FACS staining of blood, spleen and liver cells 
Cells  were  harvested  and  centrifuged  at  1500  rpm  for  five  minutes. 
Erythrocytes  were  lysed  by  resuspending  the  cell  pellet  with  5  ml  0.83% 
NH4Cl, wait for two minutes and adding 5 ml RPMI containing 10% FBS to 
stop the reaction. Around 10
6 cells were transferred to a V-bottom 96-well   96
plate. The cells were washed once by spinning the plate at 1600 rpm for five 
minutes  at  4°C,  resuspending  with  150  µl  FACS  PBS/staining  buffer  and 
spinning  again  for  five  minutes.  The  cells  were  stained  with  fluorocrome 
labeled antibody of choice in 50 µl PBS/staining buffer for at least 20 minutes 
at  4°C  in  the  dark.  After  two  additional  washes  with  150  µl  PBS/staining 
buffer  the  cells  were  resuspended  in  200  µl  PBS/staining  buffer  and 
transferred  to  FACS-tubes.  Cells  were  fixed  by  addition  of  100  µl  FACS 
fixation buffer and analyzed by flow cytometry at a FACS Calibur (BD FACS 
Calibur. 
12.2.1.10  Intracellular cytokine stain (ICCS) 
Restimulation of lymphocytes 
Cytotoxic T lymphocytes (CTLs) produce Interferon   (IFN ) after stimulation; 
therefore  intracellular  staining  for  IFN   was  used  to  quantify  specific  and 
functionally competent CTLs. 
100 µl lymphocytes at 10
7 cells/ml in RPMI 10% FCS, 50 µl of the specific 
stimulant (8 µg/ml CYP2D6 20-mers) and 50 µl RPMI 10% FCS containing 4 
µg/ml Brefeldin A (to block secretion of IFN ) were added per well of a flat-
bottom 96 well plate. Negative and positive controls were included adding 
50µl of medium or 50µl of 20 ng/ml Phorbol 12-myristate 13-acetate (PMA, T 
cell activator) and 2 mg/ml Ionomycin respectively. The plate was incubated 
for six hours or overnight at 37°C, 5% CO2. The cells were resuspended and 
transferred to a 96-well V-bottom plate and ready for staining. 
Staining 
After the cells were washed twice by resuspending with 150 µl PBS/staining 
buffer and spinning at 1600 rpm for five minutes at 4°C the cells were stained 
with  fluorocrome  labeled  anti-CD8  and/or  anti-CD4  antibody  in  50  µl 
PBS/staining  buffer  for  at  least  20  minutes  at  4°C  in  the  dark.  After  two 
additional washes with 150 µl PBS/staining buffer the cells were fixed and 
permeabilised with 100 µl of PFA/saponin solution for 10 minutes at room 
temperature. After the cells were washed twice by resuspending with 150 µl   97
PBS/saponin buffer and spinning at 1600 rpm for seven minutes at 4°C the 
cells  were  stained  with  PE-conjugated  anti-mouse-IFN   antibody  in  50  µl 
PBS/saponin buffer for 30 minutes at 4°C in the dark. After washing the cells 
two times with PBS/saponin buffer and once with PBS/staining buffer the 
cells  were  resuspended  in  200  µl  PBS/staining  buffer  and  transferred  to 
FACS-tubes. Cells were fixed by addition of 100 µl FACS fixation buffer and 
analyzed by flow cytometry. 
12.2.1.11  Adenovirus production 
HEK-293 cells were cultivated in 175 cm
2 flasks in 293-medium (DMEM + 
Glutamax containing 10% FCS, 1% penicillin, 1% streptomycin, 1% HEPES 
and 1% non-essential aa). Medium was removed from the confluent flasks 
and cells were infected with either Ad-GFP or Ad-2D6 with a MOI of 50 in a 
total volume of 15 ml 293-medium. After four hours incubation at 37°C, 5% 
CO2 15 ml pre-warmed 293-medium was added and the cells were incubated 
at 37°C, 5% CO2 for three days or until most cells were detached as clusters. 
The  content  of  all  flasks  was  transferred  to  50  ml  falcon  tubes  and 
centrifuged  at  1100  rpm  for  five  minutes  at  4°C.  After  centrifugation  the 
supernatant was discarded and three pellets were combined in 1 ml 293-
medium.  The  cells  were  transferred  to  cryotubes,  snap-frozen  in  liquid 
nitrogen and stored for later purification at -80°C. 
12.2.1.12  Adenovirus purification 
Cryotubes containing adenovirus-infected cells were put through four rapid 
thaw/freeze cycles by thawing them at 37°C, vortexing and refreeze in liquid 
nitrogen.  The  resulting  cell  lysate  was  pooled  in  a  15 ml  falcon  tube  and 
centrifuged at 1500 g for 10 minutes at 4°C. The supernatant was transferred 
to a 50 ml falcon tube and mixed with 18 ml 293-medium. Very slowly 3 ml of 
the  cleared  cell  lysate  was  transferred  onto  a  CsCl  gradient  previously 
prepared by overlaying 4 ml 40% CsCl in PBS with 4.5 ml 15% CsCl in PBS 
in an ultracentrifuge tube. The cell lysate was centrifuged at 25’400 rpm for 
17  hours  at  4°C  resulting  in  an  upper  (immature  virus)  and  lower  (mature   98
virus) virus band. To collect the mature virus a 23G needle connected to a 2 
ml syringe was carefully inserted into the ultracentrifuge tube directly under 
the  lower  virus  band  and  the  virus  was  slowly  aspirated.  The  virus  was 
transferred to a slide-a-lyzer cassette (10 kDa) and dialyzed against 2 liter 
cold  PBS  for  six  hours  and  then  over  night  after  a  PBS  change.  In  the 
morning the virus was collected and transferred to a 15 ml falcon tube. After 
the virus particle concentration was determined by a protein assay the virus 
was diluted in PBS and glycerol was added to a 10% final concentration. The 
virus was then transferred to cryotubes, snap-frozen in liquid nitrogen and 
stored at -80°C. 
12.2.1.13  Cytopathic effect assay 
A  cytopathic  effect  assay  was  performed  to  determine  Adenovirus  titers 
(110). The assay was performed in tissue culture grade 96-well plates. 
90 µl of DMEM 3% FCS was added to each well of a 96-well plate. Virus was 
diluted 1:100 in DMEM 3% FCS and 10 µl were added in triplicates to wells 
of  the  first  column.  Dilutions  were  made  with  a  multi-channel  pipette  by 
taking  10  µl  from  the  first  column,  adding  to  the  next  column,  mixing, 
carrying over 10 µl etc, which corresponded to a stepwise dilution of 1:10. 
Tips were changed after each dilution step. 
To  each  well  of  the  96-well  plates,  3-5x10
4  HEK-293  cells  were  added 
starting from the side with the highest virus dilution and the plates were put 
into  a  5%  CO2  incubator  at  37°C  for  5-10  days  or  until  a  confluent  cell-
monolayer  has  formed.  After  incubation  90  µl  of  medium  were  carefully 
removed  from  each  well  and  cells  were  fixed  by  addition  of  150  µl  10% 
formaldehyde in PBS for 10 minutes at room temperature. After staining for 
five minutes with 0.1% crystal violet the plates were washed with water and 
dried inverted on absorbent paper. The viral titer is defined as the titer, which 
causes lysis of the cells in 50% of the wells in a given dilution and is defined 
as tissue culture infectious dosis 50% (TCID50 units). TCID50 are calculated by 
the Reed-Muench method as follows:   99
Proportionate distance =
(% positive above 50%)   50%
(% positive above 50%)   (% positive below 50%)
 
log ID50 = (log dilution above 50%)+ (proportionate distance   log dilution factor) 
TCID50 per unit volume =
1
ID50
 
1
virusvolume inoculation
 
12.2.1.14  Immunohistological stainings 
Immunohistochemical stainings 
Livers were harvested at the times indicated, immersed in Tissue-Tek OCT, 
and  quick-frozen  on  dry  ice.  6  µm  tissue  sections  were  cut  using  a 
cryomicrotome and mounted on sialin-coated slides. After fixing the sections 
in 90% ethanol at -20°C for 15 minutes, the sections were put on a paper 
towel to dry for 10 minutes and circles were drawn around the specimen with 
a wax pencil. The sections were washed two times in PBS for two minutes 
and incubated in 0.3% H2O2/0.1% Na-azid in PBS for 15 minutes at room 
temperature. After washing two times in PBS for two minutes one drop of 
avidin was placed on each specimen and incubated for 10 minutes at room 
temperature. The sections were washed again and one drop of biotin was 
placed  on  each  specimen  and  incubated  for  10  minutes  at  room 
temperature. After an additional washing step, a few drops of 10% FBS in 
PBS  was  added  and  incubated  for  15 minutes  at  room  temperature.  The 
10% FBS in PBS was tapped off, the sections were washed quickly in PBS 
and 100 µl of the first antibody diluted 1:200 in 10% FBS in PBS was added 
on  each  specimen  and  incubated  for  one  hour  at  room  temperature  in  a 
humidified chamber. After tapping off the first antibody solution, the sections 
were washed two times in PBS for four minutes and 100 µl of biotinylated 
secondary antibody diluted 1:200 in 10% FBS in PBS was added on each 
specimen and incubated for 45 minutes at room temperature in a humidified 
chamber. The secondary antibody solution was tapped off and sections were 
washed two times for four minutes in PBS. One drop of ABC reagent solution 
was  added  on  each  specimen  and  incubated  for  30  minutes  at  room 
temperature. After tapping off the remaining ABC reagent and two washes in   100
PBS  for  four  minutes  100  µl  peroxidase  substrate  was  added  on  each 
specimen and incubated for five minutes at room temperature. The reaction 
was stopped by washing in PBS and the sections were counterstained in 
hematoxylin solution for five minutes at room temperature and washed two 
times  in  PBS.  After  adding  two drops  of  aquamount  onto  each  section  a 
coverslip was placed onto each slide. The sections were then incubated at 
room  temperature  for more  then  two  hours  and  pictures  were  made  at  a 
Microscope (Biozero BZ-8000, Keyence). 
Sirius red staining of collagen fibers 
Livers were harvested at the times indicated, immersed in Tissue-Tek OCT, 
and  quick-frozen  on  dry  ice.  6-µm  tissue  sections  were  cut  using  a 
cryomicrotome and mounted on sialin-coated slides. After fixing the sections 
in 90% ethanol at -20°C for 15 minutes, the sections were put on a paper 
towel to dry for 10 minutes and circles were drawn around the specimen with 
a wax pencil. 120 µl Sirius red solution was added on each specimen and 
incubated for one hour at room temperature. After washing two times in 0.01 
N HCl for two minutes, the sections were rinsed in H2O and dehydrated in 
three changes of absolute ethanol for one minute each. The sections were 
incubated  two  times  in  xylene  for  two  minutes  and  a  few  drops  of  Roti-
Histokit I was placed onto each slide and covered with a coverslip. 
Immunofluorescence stainings 
Livers were harvested at the times indicated, immersed in Tissue-Tek OCT, 
and  quick-frozen  on  dry  ice.  6-µm  tissue  sections  were  cut  using  a 
cryomicrotome and mounted on sialin-coated slides. After fixing the sections 
in 90% ethanol at -20°C for 15 minutes, the sections were put on a paper 
towel to dry for 10 minutes and circles were drawn around the specimen with 
a wax pencil. The sections were washed two times in PBS for two minutes 
and incubated for 30 minutes with PBS containing 10% FBS. After tapping 
off the PBS/FCS blocking solution the sections were washed in PBS and the 
first antibody diluted 1:200 in PBS containing 10% FBS was added to the   101
sections and incubated for two hours at room temperature in the dark. After 
washing  three  times  in  PBS  for  four  minutes  the  fluorescent-labeled 
secondary  antibody  diluted  1:200  in  10%  FBS  PBS  was  added  and  the 
sections were incubated for one hour at room temperature in a humidified 
chamber. The secondary antibody solution was tapped off and the sections 
were  washed  three  times  in  PBS  for  four  minutes  and  then  mounted  in 
immunofluore mounting medium. 
12.2.1.15  Serum values for liver damage 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
ALT  and  AST  were  determined  by  using  serum  aminotransferase  enzyme 
activity  assays  (BioTron  Diagnostics  Inc.).  In  brief,  37.5  µl  of  serum 
glutamate-pyruvate  transaminase  (SGPT)  reagent  or  serum  glutamate-
oxalacetate  transaminase  (SGOT) reagent respectively,  were  added  to  96-
well flat bottom microtiterplates. After addition of 7.5 µl sera and standards, 
plates were incubated for 40 minutes at 37°C. After incubation 37.5 µl of ALT 
or AST color developer A were added and plates were incubated for further 
15 minutes at 37°C. In the end 150 µl ALT or AST color developer B was 
added and after 5 minutes incubation at room temperature the OD was read 
at 540 nm using a microplate reader (Sunrise, Tecan). ALT and AST Serum 
levels (Units/l) were calculated using the normal and abnormal standards. 
Alkaline Phosphatase (AP) and Gamma Glutamyl Transpeptidase (GGT) 
AP and GGT were measured by the central laboratory of the Clinic of the 
Johann  Wolfgang  Goethe  University  in  Frankfurt  am  Main.  The  sera  were 
diluted 1:4 prior to measurement. 
12.2.1.16  Preparation of microsomes from liver homogenates 
Livers were harvested and homogenized with a tissue homogenizer in 20 ml 
PBS. To get rid of the large cell debris and nuclei the liver homogenate was 
centrifuged at 3’000 g for 15 minutes and the supernatant was transferred to 
a new tube. The supernatant was then centrifuged at 20’000 g for 15 minutes   102
to  pellet  the  mitochondria  and  larger  membrane  fractions.  After  the 
supernatant was transferred to a new tube it was centrifuged at 100’000 g for 
one hour. After the supernatant containing the cytoplasm was discarded the 
pellet  containing  the  microsomes  was  resuspended  in  5  ml  PBS  and  the 
protein concentration was measured. 
12.2.1.17  MACS purification of B cells and T cells 
Lymphocytes were harvested either from the spleen or liver and resuspended 
at  a  concentration  of  1x10
8  cells/ml  in  PBS  containing  2%  FCS  and  5% 
normal rat serum in a FACS tube. A small sample was collected for FACS 
analysis  of  pre-separated  cells.  EasySep  negative  selection  mouse 
enrichment cocktail was added at a concentration of 50 µl/ml of cells and the 
suspension was incubated for 15 minutes at 4°C. After incubation EasySep 
biotin selection cocktail was added at a concentration of 100 µl/ml of cells 
and  after  15  minutes  incubation  at  4°C  magnetic  nanoparticles  at  a 
concentration of 50 µl/ml of cells were added and the cell suspension was 
mixed by pipetting. After 15 minutes incubation at 4°C the cell suspension 
was filled up to 2.5 ml with PBS containing 2% FCS and mixed. The cells 
were  then  placed  for  five  minutes  in  an  EasySep  magnet  at  room 
temperature and after incubation the EasySep magnet was inverted in one 
continuous motion and the cell suspension collected in a FACS tube. This 
separation  process  was  repeated  two  more  times.  A  small  sample  was 
collected for FACS analysis of separated cells and cells were used for further 
experiments. 
12.2.2  Molecular biological methods 
12.2.2.1  Mouse tail DNA isolation 
Tail biopsies (0.3 cm) were digested overnight with 5 µl of proteinase K (10 
mg/ml) in 500 µl of proteinase K buffer at 55°C. 75 µl of 8M KOAc and 500 µl 
chloroform were added and the tubes were inverted several times, incubated 
at -70°C for 15 minutes and centrifuged for five minutes at 14’000 rpm in a 
micro-centrifuge. Then the supernatant was transferred to new tubes, 1 ml of   103
ethanol  was  added  and  the  tubes  were  inverted  several  times.  After 
centrifugation at 14’000 rpm for 10 minutes the supernatant was removed 
and the DNA pellet was washed with 1 ml of 70% ethanol. DNA was air dried 
for 10 to 30 minutes and then re-dissolved in 100 µl TE buffer and stored at 
4°C. 
12.2.2.2  RNA extraction from tissues 
Tissues were harvested and homogenized in 1 ml TRI reagent per 50-100 mg 
tissue with a tissue homogenizer. Per 50-100 mg tissue 0.2 ml chloroform 
was added and the homogenate was vortexed for 15-20 seconds. After 2-15 
minutes incubation at room temperature the homogenate was centrifuged at 
12’000 g for 15 minutes at 4°C. After centrifugation the upper aqueous phase 
was  transferred  into  a  new  tube  and  0.5 ml  isopropanol  was  added.  The 
tubes were inverted several times and after an incubation of 5-10 minutes 
centrifuged at 12’000 g for eight minutes. The supernatant was removed and 
the RNA pellet was washed with 1 ml 75% ethanol. After centrifugation at 
7’500 g for five minutes the RNA pellet was air dried for 5-10 minutes and 
then re-dissolved in an appropriate volume of H2ODEPC and incubated at 56°C 
for 10 minutes. The RNA concentration was determined on a Nano-drop (ND-
1000 Spectrometer) and the RNA was stored at -80°C for further usage. 
12.2.2.3  Polymerase chain reaction (PCR) 
PCR  was  used  to  amplify  the  transgenic  insert  of  the  CYP2D6  mice  for 
screening (77). 
The components of the PCR reaction: 
ddH2O  19.9 µl 
10x PCR buffer  2.5 µl 
10 mM dNTP-Mix  0.5 µl 
10 µM CYP2D6 R Primer  0.5 µl 
10 µM CYP2D6 F Primer  0.5 µl 
TAQ-Polymerase  0.1 µl 
DNA  1 µl   104
Cycling: 
5 minutes initial denaturation at  94°C 
  
35 cycles:   
30 seconds denaturation at  94°C 
30 seconds primer annealing at  56°C 
1 minute elongation at   72°C 
  
3 minute additional elongation at  72°C 
Cool to   4°C 
For all reactions a water sample was included as negative control to confirm 
the viability of the PCR result. PCR products were analyzed by agarose gel 
electrophoresis. 
12.2.2.4  DNA agarose gel electrophoresis 
Separation of DNA fragments of different sizes was achieved by agarose gel 
electrophoresis. A 1% agarose gel was routinely used as the expected size 
of the fragments was between 0.5 and 10 kb. Agarose was dissolved in TAE 
buffer  by  boiling.  After  cooling  to  hand  temperature  1  µg/ml  Ethidium 
bromide  was  added  while  stirring.  The  solution  was  poured  into  an 
appropriate gel tray with inserted combs. Following cooling and solidification 
the combs were removed and the gel was placed into an electrophoresis 
container containing 1x TAE as running buffer. The slots were loaded with 
DNA  samples  to  which  16%  of  6x  DNA  loading  dye  was  added.  An 
appropriate  DNA  molecular  weight  marker  was  run  in  parallel  in  order  to 
evaluate molecular weights of the DNA fragments. The voltage applied for 
the separation was 5V per cm space between the two electrodes. The gels 
were run for 20-120 minutes and the separated DNA bands were visualized 
and pictures were taken under UV irradiation (300 nm). 
12.2.2.5  Quantification of DNA, RNA and proteins 
DNA  and  RNA  concentrations  were  measured  on  a  Nano-drop  (ND-1000 
Spectrometer).   105
Protein concentrations were measured with a Bio-rad Protein assay and the 
standard protocol was followed. In brief, 50 µl PBS and 50 µl protein sample 
were mixed and 2-fold serial diluted with PBS over 11 steps of a 96-well flat 
bottom plate. The standard solution (2 mg/ml) was serial diluted 2-fold with 
PBS  in  duplicates  and  two  wells  were  filled  with  100  µl  PBS  as  blank 
controls. Color developer was diluted 1:5 in PBS, 200 µl were added to all 
wells  and  the  plate  was  measured  at  595  nm  with  an  ELISA  microplate 
reader (Sunrise, Tecan). 
12.2.2.6  B cell epitope mapping 
Arrays of 162 staggered 12mer synthetic peptides covering the entire human 
CYP2D6  sequence  were  covalently  linked  to  nylon  membranes  (custom 
SPOTs  service;  Sigma-Aldrich).  The  N-terminal  aa  of  the  12mer  peptides 
were shifted within the human CYP2D6 by three aa residues. Membranes 
were blocked for six hours at room temperature in 2% dry milk/PBS before 
they  were  incubated  overnight  at  4°C  with  serum  diluted  1:200  in  SPOT 
washing buffer. Membranes were washed four times in SPOT washing buffer 
and were then incubated at room temperature for two hours with IRDye800 
labeled secondary antibody diluted 1:20’000 in SPOT washing buffer. After 
two washes in SPOT washing buffer and three washes in PBS, fluorescence 
intensity was analyzed using an infrared imaging system (Odyssey; LI-COR 
Bioscience GmbH). 
12.2.2.7  SDS PAGE 
For the separation of proteins, first an appropriate separating gel (10% for 
cytochrome  P450  2D6  and  12%  for  adenovirus  type  5  separation)  was 
prepared using a 0.75 mm spacer: 
  10%  12% 
Acrylamide  3.33 ml  4 ml 
Lower gel buffer  2.5 ml  2.5 ml 
Distilled water  4.07 ml  3.4 ml   106
SDS (20% w/v)  50 µl  50 µl 
TEMED  5 µl  5 µl 
APS (10% w/v)  50 µl  50 µl 
Just after adding the TEMED and APS, the acrylamide solution was poured 
to about 5.3 cm from the bottom. During polymerisation an isopropanol or 
water overlay was added. After more then one hour of polymerisation the 
overlay was removed and a 3% stacking gel was prepared: 
  10% 
Acrylamide  0.5 ml 
Upper gel buffer  1.25 ml 
Distilled water  3.25 ml 
SDS (20% w/v)  25 µl 
TEMED  5 µl 
APS (10% w/v)  25 µl 
Immediately after pouring, the comb was added. Samples were heated for 5 
minutes to 95°C in 1x Laemmli sample buffer. After polymerization, the comb 
was removed and the wells were washed with 1x Running buffer to remove 
any unpolymerised acrylamide. The gels were mounted in the electrophoresis 
apparatus  and  the  inner  chamber  was  filled  with  1x  Running  buffer.  The 
samples were loaded and the outer chamber was also filled with Running 
buffer. Electrophoresis was performed at 125–140 V until the front reached 
the bottom of the gel (about one hour). 
12.2.2.8  Western blotting 
A PVDF membrane (5.2 x 8.5 cm) was prepared and put into methanol for 
five seconds. The membrane and four pieces of Whatman paper (6 x 9 cm) 
were  equilibrated  in  transfer  buffer  for  five  minutes.  The  gel  and  the 
membrane were put into the blotting apparatus together with the Whatman 
paper  in  the  following  order:  2  Whatman  paper  –  membrane  –  gel  –  2 
Whatman  paper.  Air  bubbles  in between  were  removed  by  rolling  a  glass   107
pipette  over  the  stock.  The  proteins  were  blotted  onto  the  membrane  at 
constant 125 mA for one and a half hours. 
For  blocking,  the  membrane  was  incubated  for  two  hours  at  room 
temperature in PBS 5% milk containing 0.1% Tween-20 on a shaker. The 
primary antibody was diluted 1:2’000 (anti-Cytochrome P450 2D6) or 1:4’000 
(anti-Adenovirus  type  5)  in  PBS  5% milk  containing  0.1%  Tween-20.  The 
membrane  was  incubated  over  night  at  4°C  together  with  10  ml  of  the 
antibody solution. After washing six times with PBS 5% milk containing 0.1% 
Tween-20 for 5 minutes, the second stage antibody, an IRDye conjugated 
monoclonal anti-rabbit IgG was added at a dilution of 1:20’000 in 10ml PBS 
5% milk containing 0.1% Tween-20. The membrane was incubated together 
with this solution at room temperature for two hours, washed three times 
with PBS 5% milk containing 0.1% Tween-20 and another three times with 
PBS for 5 minutes. The separated protein bands were visualized and pictures 
were taken on a Pharos (Pharos FX Plus Molecular Imager, Bio Rad) 
12.2.3  Experiments with mice 
12.2.3.1  Serum collection 
Mice were anesthetized with isofluran and blood samples were taken retro-
orbitally with a heparin coated capillary and collected in an eppendorf tube. 
The  blood  was  then  centrifuged  for  10  minutes  at  6’000  rpm  in  a 
microcentrifuge  and  serum  was  transferred  to  a  new  eppendorf  tube  and 
stored at -80°C. Serum was collected at various time points as indicated. 
12.2.3.2  Injections 
Unless  described  otherwise,  mice  were  injected  with  a  total  of  2  x  10
10 
particles of Ad-2D6 or Ad-GFP (i.p. and i.v.). 
Intravenous injections (i.v.) 
Mice were anesthetized with isofluran and 100 µl virus, human recombinant 
CYP2D6  alone  or  in  combination  with  CpG  or  pIC  were  injected  with  a 
syringe retro-orbitally at the time points indicated.   108
Intraperitoneal injections (i.p.) 
Mice were held in one hand and 100 µl virus were injected with a syringe 
intra peritoneal.  
Subcutaneous injections (s.c.) 
Mice were anesthetized with isofluran and 100 µl CFA or IFA emulsified using 
two  glass  syringes  were  injected  with  a  syringe  under  the  skin  at  several 
locations on the back of the mouse. 
12.2.3.3  Liver perfusions 
Mice were anesthetized with isofluran and killed by cervical dislocation. After 
the abdomen had been opened the hepatic vein and hepatic artery were cut 
and the liver was perfused with ~5 ml PBS through the hepatic portal vein. 
The liver was removed and appropriately stored for further processing.   109
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